

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2019254237 B2**

(54) Title
Method for preventing or treating side effects of cancer therapy

(51) International Patent Classification(s)
A61K 31/21 (2006.01) **A61P 17/02** (2006.01)
A61P 17/00 (2006.01)

(21) Application No: **2019254237** (22) Date of Filing: **2019.04.15**

(87) WIPO No: **WO19/201195**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	201810339975.5		2018.04.16		CN

(43) Publication Date: **2019.10.24**

(44) Accepted Journal Date: **2025.01.30**

(71) Applicant(s)
OnQuality Pharmaceuticals China Ltd.

(72) Inventor(s)
ZHANG, Shiyi;WU, Zhaoyu;LIU, Chao;YANG, Linan;CHEN, Leying;LUO, Jie

(74) Agent / Attorney
Madderns Pty Ltd, GPO Box 2752, Adelaide, SA, 5001, AU

(56) Related Art
WO 2014/160628 A2
KRUZLIAK P., et al., "Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension", ANGIOGENESIS, (2013), vol. 16, pages 289 - 295.
WO 2010/037095 A2
WO 01/80890 A2
WO 2019/114705 A1

(12) 按照专利合作条约所公布的国际申请

(19) 世界知识产权组织
国际局



(10) 国际公布号

WO 2019/201195 A1

(43) 国际公布日

2019 年 10 月 24 日 (24.10.2019)

WIPO | PCT

(51) 国际专利分类号:

A61K 31/21 (2006.01) A61P 17/02 (2006.01)

A61P 17/00 (2006.01)

(21) 国际申请号:

PCT/CN2019/082623

(22) 国际申请日:

2019 年 4 月 15 日 (15.04.2019)

(25) 申请语言:

中文

(26) 公布语言:

中文

(30) 优先权:

201810339975.5 2018年4月16日 (16.04.2018) CN

(71) 申请人: 上海岸阔医药科技有限公司(ONQUALITY PHARMACEUTICALS CHINA LTD.) [CN/CN]; 中国上海市宝山区爱辉路 201 号 3 幢 5028 室, Shanghai 200431 (CN)。

(72) 发明人: 张诗宜(ZHANG, Shiyi); 中国上海市闵行区剑川路955号305室, Shanghai 200240 (CN)。吴兆宇(WU, Zhaoyu); 中国上海市闵行区剑川路955号305室, Shanghai 200240 (CN)。刘超(LIU, Chao); 中国上海市闵行区剑川路955号305室, Shanghai 200240 (CN)。杨立楠(YANG, Linan); 中国上海市闵行区剑川路955号305室, Shanghai 200240 (CN)。陈乐颖(CHEN, Leying); 中国上海市闵行区剑川路955号305室, Shanghai 200240 (CN)。罗洁(LUO, Jie); 中国上海市闵行区剑川路955号305室, Shanghai 200240 (CN)。

(74) 代理人: 上海巔石知识产权代理事务所(普通合伙)(SHANGHAI DIANSHI PARTNERS, P.C.); 中国上海市浦东新区祖冲之路2277弄1号楼708室张琤、蒋舫玮, Shanghai 201203 (CN)。

(81) 指定国(除另有指明, 要求每一种可提供的国家保护): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS,

JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW。

(84) 指定国(除另有指明, 要求每一种可提供的地区

保护): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), 欧亚 (AM, AZ, BY, KG, KZ, RU, TJ, TM), 欧洲 (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)。

根据细则4.17的声明:

- 关于申请人有权要求在先申请的优先权(细则4.17(iii))
- 发明人资格(细则4.17(iv))

本国际公布:

- 包括国际检索报告(条约第21条(3))。

(54) Title: METHOD FOR PREVENTING OR TREATING SIDE EFFECTS OF CANCER THERAPY

(54) 发明名称: 预防或治疗肿瘤疗法副作用的方法

(57) Abstract: Disclosed in the present invention is an application of a nitric oxide releasing agent in preparing a medication. The medication is used for preventing or treating a disease or disorder associated with administration of a VEGFR inhibitor and/or a VEGF inhibitor. The present application also provides a method for preventing or treating a disease or disorder associated with administration of a VEGFR inhibitor and/or a VEGF inhibitor. The method may comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of nitric oxide releasing agent.

(57) 摘要: 本发明公开了一氧化氮释放剂在制备药物中的用途, 所述药物用于预防或治疗与施用VEGFR抑制剂和/或VEGF抑制剂相关的疾病或病症。本申请还提供预防或者治疗与施用VEGFR抑制剂和/或VEGF抑制剂相关的疾病或病症的方法, 所述方法可包括向有需要的受试者施用预防或治疗有效量的一氧化氮释放剂。



WO 2019/201195 A1

METHOD FOR PREVENTING OR TREATING SIDE EFFECTS OF CANCER THERAPY**INVENTION FIELD**

The present application relates to treatment of diseases, for instance a method of preventing or treating diseases or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor.

BACKGROUND

Mutation or overexpression of vascular endothelial growth factor receptor (VEGFR) has been found to be associated with a variety of cancers, and patients suffering from such cancers can be treated by the therapy of inhibiting VEGFR and/or VEGF (e.g., administering a VEGFR inhibitor and/or VEGF inhibitor). However, this type of therapy commonly causes serious side effects, especially in skin, facial organs and gastrointestinal tract. The serious side effects caused by therapies of inhibiting VEGFR and/or VEGF will compromise the life quality of patients, reducing the compliance and resistance of patients, causing medicament withdrawal or underdosage of the VEGFR/VEGF inhibitor thereby adversely affecting the therapeutic effect, or even resulting in an accelerated development of diseases and shortened survival of patients.

There is no effective therapeutic regimen controlling the side effects associated with administration of a VEGFR inhibitor and/or VEGF inhibitor presently. Thus, there is an urgent need for a therapeutic regimen capable of controlling these side effects successfully.

SUMMARY OF THE INVENTION

The present application provides a method of preventing or treating disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. In particular, the present application relates to a use of a nitric oxide releasing agent for preventing or treating a disease or disorder associated with administration of VEGFR inhibitor and/or VEGF inhibitor in a subject, that may effectively control the side effects caused by VEGFR inhibitor and/or VEGF inhibitor, such as, skin tissue disease or disorder associated with administration of said VEGFR inhibitor and/or VEGF inhibitor, facial organ disease or disorder associated with administration of said VEGFR inhibitor and/or VEGF inhibitor and/or gastrointestinal disease or disorder associated with administration of said VEGFR inhibitor and/or VEGF inhibitor, and the like.

Different from using higher dosage (such as, about 2%) of nitric oxide releasing agent (such as, nitroglycerin) used to prevent or treat angina, in this application, surprisingly, the dosage of nitric oxide releasing agent (such as, nitroglycerin) used may be as low as 0.5% or less, such as less than 0.4% less than

0.3%, less than 0.25%, less than 0.2%, less than 0.15%, or less than 0.1%, and is effective in preventing or treating side effects associated with tumor therapy, for instance, effective in preventing or treating disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor, for example, effective in preventing or treating skin tissue disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor, facial organ disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor and/or gastrointestinal disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor, and the like. Before the present application, nitric oxide releasing agent has not been used to treat the above disease or disorder.

In one aspect, the present application provides a use of a nitric oxide releasing agent in the preparation of a medicament. The medicament may be used for preventing or treating a disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor in a subject. For instance, the disease or disorder may be caused by administration of the VEGFR inhibitor and/or the VEGF inhibitor. In some embodiments, the VEGFR inhibitor or VEGF inhibitor is used for treating tumor. In some embodiments, the location of the disease or disorder is different from that of tumor. In some embodiments, the medicament is formulated to be suitable for topical administration. In some embodiments, the location of said topical administration is not the occurrence site of cancer or potential metastatic site of cancer. In some embodiments, the concentration of the nitric oxide releasing agent in the medicament is about 0.05% (w/w) to about 0.5% (w/w). In some embodiments, the medicament is formulated to be suitable for external administration. In some embodiments, the medicament is formulated as ointment. In some embodiments, the medicament further comprises one or more additional active ingredients. In some embodiments, the medicament does not substantially affect the therapeutic effect of the VEGFR inhibitor and/or the VEGF inhibitor (e.g., the effect of treating cancers). In some embodiments, the nitric oxide releasing agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, sodium nitrate, isoamyl nitrite, sodium nitrite, molsidomine, sodium nitroprusside, S-nitrosothiol silica nanospheres, S-nitrosoethanedithiol chitin, oligo-propylenediamine-grafted chitosan NONOate, N-nitrosodibutylamine, hydroxyldiazenesulfonic acid-1-oxide disodium salt, streptozocin, nicorandil, and *Nitrosomonas europaea*. In some embodiments, the disease or disorder is hand-foot syndrome.

In another aspect, the present application provides a nitric oxide releasing agent for preventing or treating a disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor in a subject. For instance, the disease or disorder may be caused by administration of a VEGFR inhibitor and/or the VEGF inhibitor.

In another aspect, the present application provides a method of preventing or treating a disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject, comprising a prophylactically or therapeutically effective amount of the nitric oxide releasing agent administering to the subject. In some embodiments, the subject comprises a human or non-human animal. For instance, the non-human animal may comprise an animal selected from the group consisting of monkey, chicken, goose, cat, dog, mouse, and rat. In some embodiments, the subject may comprise cancer subject. In some embodiments, the subject has been, is being and/or will be administrated the VEGFR inhibitor or VEGF inhibitor. In some embodiments, the subject suffers or susceptible to suffer said disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. In some embodiments, the severity of the disease or disorder increase after administrating the VEGFR inhibitor and/or VEGF inhibitor. In some embodiments, the subject has not suffered the disease or disorder before administrating the VEGFR inhibitor or VEGF inhibitor. In some embodiments, the VEGFR inhibitor and/or VEGF inhibitor doesn't comprise the nitric oxide releasing agent. In some embodiments, the VEGFR inhibitor and/or VEGF inhibitor doesn't comprise a nitroglycerin. In some embodiments, the disease or disorder is caused by administration of the VEGFR inhibitor and/or the VEGF inhibitor to the subject. For instance, the nitric oxide releasing agent may be administered before, simultaneously with, or after the administration of the VEGFR inhibitor and/or the VEGF inhibitor to the subject. In some embodiments, the VEGFR inhibitor and/or the VEGF inhibitor is used to treating tumor. In some embodiments, the location of the disease or disorder is different from that of tumor. In some embodiments, the nitric oxide releasing agent is topically administered. In some embodiments, the location of said topical administration is not the occurrence site of cancer or potential metastatic site of cancer. In some embodiments, the nitric oxide releasing agent is administered at a concentration of about 0.0001% (w/w) to about 50% (w/w). In some embodiments, the nitric oxide releasing agent is external administered. In some embodiments, the nitric oxide releasing agent is contained in an ointment for administration. In some embodiments, the nitric oxide releasing agent is administered together with one or more additional active ingredients. In some embodiments, the administration of the nitric oxide releasing agent does not substantially affect the therapeutic effect of the VEGFR inhibitor and/or the VEGF inhibitor.

In another aspect, the present application provides a combination of medicaments or kit. The combination of medicaments or kit may comprise: 1) a VEGFR inhibitor and/or a VEGF inhibitor; and 2) a nitric oxide releasing agent. In some embodiments, the VEGFR inhibitor and/or the VEGF inhibitor and the nitric oxide releasing agent are not mixed with each other. In some embodiments, the VEGFR inhibitor and/or the VEGF inhibitor and the nitric oxide releasing agent are each independently present in a separate container. In some

embodiments, the nitric oxide releasing agent is formulated to be suitable for external administration. In some embodiments, the nitric oxide releasing agent is formulated as ointment. In some embodiments, the concentration of the nitric oxide releasing agent is about 0.0001% (w/w) to about 50% (w/w). In some embodiments, the nitric oxide releasing agent of 2) is capable of preventing or treating the diseases or disorders caused by the VEGFR inhibitor and/or the VEGF inhibitor of 1). In some embodiments, the nitric oxide releasing agent of 2) does not substantially affect the therapeutic effect of the VEGFR inhibitor and/or the VEGF inhibitor of 1). In some embodiments, the nitric oxide releasing agent of 2) is administered before, simultaneously with, or after the administration of the VEGFR inhibitor and/or the VEGF inhibitor of 1).

In another aspect, the present application provides a method comprising administering a nitric oxide releasing agent to a subject, wherein the subject has been, is being and/or will be administered with VEGFR inhibitor and/or VEGF inhibitor, and suffers a disease or disorder associated with administration of VEGFR inhibitor and/or VEGF inhibitor, wherein the disease or disorder is hand-foot syndrome, the nitric oxide releasing agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, sodium nitrate, isoamyl nitrite, sodium nitrite, molsidomine, sodium nitroprusside, S-nitrosothiol silica nanospheres, S-nitrosoethanedithiol chitin, oligo-propylenediamine-grafted chitosan NONOate, N-nitrosodibutylamine, hydroxyldiazenesulfonic acid-1-oxide disodium salt, streptozocin, nicorandil, and *Nitrosomonas europaea*, and the concentration of said nitric oxide releasing agent is about 0.05% (w/w) to about 0.5% (w/w).

In another aspect, the present application provides a method of preventing or treating a disease or disorder, comprising administering nitric oxide releasing agent to a subject, wherein the subject has been, is being and/or will be administered a VEGFR inhibitor and/or VEGF inhibitor.

In another aspect, the present application provides a method of preventing or treating a disease or disorder, comprising administering a nitric oxide releasing agent to a subject that suffers the disease or disorder, wherein said disease or disorder is hand-foot syndrome, wherein the subject has been, is being and/or will be administered a VEGFR inhibitor and/or VEGF inhibitor, the concentration of the nitric oxide releasing agent in the medicament is about 0.05% (w/w) to about 0.5% (w/w), and the nitric oxide releasing agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, sodium nitrate, isoamyl nitrite, sodium nitrite, molsidomine, sodium nitroprusside, S-nitrosothiol silica nanospheres, S-nitrosoethanedithiol chitin, oligo-propylenediamine-grafted chitosan NONOate, N-nitrosodibutylamine, hydroxyldiazenesulfonic acid-1-oxide disodium salt, streptozocin, nicorandil, and *Nitrosomonas europaea*.

In another aspect, the present application provides a method comprising the steps of: 1) monitoring one or

more features of skin tissue, facial organ and/or gastrointestinal tract of a subject administrated a VEGFR inhibitor and/or VEGF inhibitor; 2) when the monitoring shows the subject suffering skin tissue disease or disorder, facial organ disease or disorder and/or gastrointestinal disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, administering the nitric oxide releasing agent to the subject.

In some embodiments, the method further comprises continuously monitoring the skin tissue disease or disorder, facial organ disease or disorder and/or gastrointestinal tract disease or disorder, and reducing or withdrawing the VEGFR inhibitor and/or VEGF inhibitor optionally.

In some embodiments, the severity of the disease or disorder increases after the administration of the VEGFR inhibitor and/or VEGF inhibitor.

In some embodiments, the subject has not suffered the disease or disorder before the administration the VEGFR inhibitor and/or VEGF inhibitor.

In some embodiments, the VEGFR inhibitor and/or VEGF inhibitor doesn't comprise the nitric oxide releasing agent. In some embodiments, the VEGFR inhibitor and/or VEGF inhibitor doesn't comprise a nitroglycerin.

In some embodiments, the disease or disorder is an epithelial disease or disorder.

In some embodiments, the administration of the VEGFR inhibitor and/or VEGF inhibitor is used to treat cancer. In some embodiments, the location of said disease or disorder is different from that of cancer.

In some embodiments, the subject is topically administrated the nitric oxide releasing agent.

In some embodiments, the subject is topically administrated the nitric oxide releasing agent at location of disease or disorder that substantially doesn't comprise a tumor cell. In some embodiments, administrate the nitric oxide releasing agent to the subject at no-cancer location.

In some embodiments, the at least one of the VEGFR inhibitors as described in the present application directly effects on a VEGFR protein and/or a nucleic acid encoding a VEGFR protein.

In some embodiments, the at least one of the VEGF inhibitors as described in the present application directly effects on a VEGF protein and/or a nucleic acid encoding a VEGF protein.

In some embodiments, the VEGFR inhibitor of the present application and /or the VEGF inhibitor of the present application is used for treating cancers.

In some embodiments, the VEGFR inhibitor of the present application comprises a small molecular VEGFR inhibitor, a protein macromolecule specifically binding to VEGFR, an RNAi inhibiting the expression of a VEGFR protein and/or an antisense oligonucleotide inhibiting the expression of a VEGFR protein.

In some embodiments, the VEGF inhibitor of the present application comprises a VEGF trapping agent and/or an agent of reducing the expression level of VEGF.

In some embodiments, the VEGFR inhibitor of the present application inhibits VEGFR1, VEGFR2 and/or VEGFR3.

In some embodiments, the VEGFR inhibitor and/or VEGF inhibitor of the present application comprises Ramucirumab, Bevacizumab, Regorafenib, Ponatinib, Cabozantinib, Lenvatinib, Sorafenib, Pazopanib, Apatinib, Axitinib, Nintedanib, Vandetanib, Sunitinib, Midostaurin, Tivozanib, Fruquintinib, Cediranib, Brivanib, Donafenib, Sulfatinib, Anlotinib, Famitinib, Tesevatinib, Vorolanib, Motesanib, Linifanib, Semaxanib, Dovitinib, Orantinib, Vatalanib, Telatinib, Glesatinib, Delitinib, Ilorasertib, Rebastinib, Golvatinib, Foretinib, Ningetinib, Tafetinib, Altiratinib, TAS-115, Chiauranib, Henatinib, 4SC-203, AAL-993, ACTB-1003, AEE-788, AMG-628, Arenobufagin, BAW2881, BIBF-1202, BMS-690514, BMS-794833, CEP-11981, CEP-5214, CP-547632, CYC116, DW532, ENMD-2076, FIIN-1, GFB-204, BFH-772, BMS599626, BMS690514, PP 121, MGCD 265 analogue, AC480, Ki 8751, KRN 633, WHI-P 154, TAK593, JI 101, AZD-2932, SCR-1481B1, Isoliquiritigenin, JNJ-26483327, KI-20227, LY2457546, ODM-203, OSI-930, PF-00337210, CGP41231, R1530, RAF265, SAR131675, Semaxinib, SIM010603, SKLB1002, SKLB610, SU 5205, SU11652, SU14813, SU-1498, SU-4312, SU5402, T-1840383, Tanshinone IIA, TAS-115, TG 100572, TG 100801, TG100572 HCl, Toceranib, Tyrosine phosphorylation inhibitor A9, Tesevatinib, XL-844, XL999, ZD4190 HCl, ZM-306416, ZM323881 HCl, ABT-510, NVP-ACC789, ADT-OH, BMS-645737, EG 00229, XL-820, SGI-7079, Endostatin, Taxifolin, Aflibercept, a pharmaceutically acceptable salt thereof and/or any combination of the foregoing.

In some embodiments, the VEGFR inhibitor and/or VEGF inhibitor of the present application is administered in combination with one or more additional therapies. The one or more additional therapies may comprise one or more additional anti-tumor therapies.

In some embodiments, the disease or disorder of the present application is caused by the VEGFR and/or VEGF inhibition.

In some embodiments, the disease or disorder of the present application comprises skin tissue disease or disorder, facial organ disease or disorder, and/or gastrointestinal disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor.

In some embodiments, the skin tissue disease or disorder, facial organ disease or disorder and/or gastrointestinal disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor of the present application comprises epithelial disease or disorder associated with administration of

the VEGFR inhibitor and/or VEGF inhibitor in the skin tissue, the facial organ and/or the gastrointestinal tract.

In some embodiments, the epithelial disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor of the present application comprises the disease or disorder associated with lesion of endothelial cell and/or disease or disorder associated with lesion of epithelial cell, and wherein the lesion of endothelial cell and/or the lesion of epithelial cell is associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The endothelial cell may comprise vascular endothelial cell. The epithelial cell may comprise skin epithelial cell, oral epithelial cell, nasal epithelial cell, gastric epithelial cell and/or intestinal epithelial cell.

In some embodiments, the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor selected from the group consisting of rash associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, pruritus associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, erythema associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerosis cutis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, alopecia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, paronychia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, pigmentation disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, oral mucositis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerostomia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, epistaxis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nasopharyngitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, cheilitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, esophagitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, esogastritis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, gastric ulcer associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, diarrhea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, vomiting associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nausea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, anorexia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, constipation associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, and/or abdominal pain associated with administration of the VEGFR inhibitor and/or VEGF inhibitor. In some embodiments, the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor comprises hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor. In some embodiments, the severity of the

disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor is Grade 1 or above, Grade 2 or above, Grade 3 or above, Grade 4 or above, and/or Grade 5 or above according to NCI-CTCAE V5.0.

In some embodiments, the nitric oxide releasing agent is capable of producing a substance selected from the group consisting of NO^+ , NO^- , N_2O , NO , N_2O_3 , NO_2 , NO_3^- and NO_2^- . For instance, the nitric oxide releasing agent is capable of directly or indirectly producing NO . In some embodiments, the nitric oxide releasing agent comprises NO .

In some embodiments, the nitric oxide releasing agent comprises a substance comprising an organic molecule, an inorganic molecule, a macromolecule, a nanomaterial, and/or an ammonia oxidizing microorganism (AOM).

In some embodiments, the nitric oxide releasing agent is nitroglycerin, isosorbide mononitrate, isosorbide dinitrate or sodium nitroprusside. In some embodiment, the nitric oxide releasing agent is nitroglycerin.

In some embodiments, the nitric oxide releasing agent comprises an inorganic molecule, and the inorganic molecule comprises nitril complex, nitrosyl complex, metal nitrosamino complex, nitrate, and/or nitrite. In some embodiments, the nitric oxide releasing agent comprises an inorganic molecule, and the inorganic molecule comprises sodium nitroprusside.

In some embodiments, the nitric oxide releasing agent comprises ammonia oxidizing microorganism (AOM), and the ammonia oxidizing microorganism (AOM) comprises ammonia oxidizing bacteria (AOB). In some embodiments, the nitric oxide releasing agent comprises ammonia oxidizing microorganism (AOM), and said ammonia oxidizing microorganism (AOM) comprises *Nitrosomonas*, *Nitrosococcus*, *Nitrospira*, *Nitrosocystis*, *Nitrosolobus* and/or *Nitrovibrio*.

In some embodiments, the nitric oxide releasing agent has a relative molecular weight of 2000 Daltons or below, 1500 Daltons or below, 1200 Daltons or below, 1000 Daltons or below, 900 Daltons or below, 800 Daltons or below, 700 Daltons or below, 600 Daltons or below, 500 Daltons or below, 400 Daltons or below, 300 Daltons or below, 200 Daltons or below, or 100 Daltons or below.

In some embodiments, the nitric oxide releasing agent comprises a macromolecule or a nanomaterial, and the macromolecule or nanomaterial comprises S-nitrosothiol silica nanospheres, S-nitrosoethanedithiol chitin, and/or oligopropylenediamine-grafted chitosan NONOate.

In some embodiments, the nitric oxide releasing agent has one or more groups as following: diazeniumdiolate, hydroxyldiazenesulfonic acid, S-nitrosothiol, furoxan, oxime, N-nitrosoamine, N-hydroxylguanidine, nitrate, nitrite, nitrate ester, nitrite ester, sydnonimine, sydnone, oxatriazol-5-imine,

oxatriazol-5-one, hydroxylamine, dioxadiazacyclobutene, N-hydroxynitrosoamine, N-nitrosoimine, hydroxyurea and metal nitrosamino complex.

Persons skilled in the art can recognize other aspects and advantages of this disclosure from the detailed description hereinafter. The following detailed description only reveals and describes exemplary embodiments of this disclosure. As those skilled in the art will recognize, this disclosure enables persons skilled in the art to modify the disclosed embodiments without departing the spirit and scope of the present application. Correspondingly, the drawings and the description in the present specification are only illustrative, but not limitative.

BRIEF DESCRIPTION OF DRAWINGS

The features of the invention as claimed in the present application are defined by the accompanying claims. The features and advantages of the inventions as disclosed herein can be better understood by referring to the exemplary embodiments and the accompanying drawings. The drawings are briefly described as follows:

FIG. 1 depicts an exemplary synthesis scheme of S-nitrosothiol silica nanospheres.

FIG. 2 depicts an exemplary synthesis scheme of S-nitrosoethanedithiol chitin.

FIG. 3 depicts an exemplary synthesis scheme of oligopropylenediamine-grafted chitosan NONOate.

FIGs. 4A-4C depict an exemplary result of cell proliferative toxicity as determined after administration of a nitric oxide releasing agent (or sildenafil) to HUVEC cells.

FIGs. 5A-5C depict an exemplary result of cell proliferative toxicity as determined after administration of a nitric oxide releasing agent (or sildenafil) to HaCaT cells.

FIGs. 6A-6C depict an exemplary result of cell proliferative toxicity as determined after administration of a nitric oxide releasing agent (or sildenafil) to HOK cells.

FIGs. 7A-7C depict an exemplary result of cell proliferative toxicity as determined after administration of a nitric oxide releasing agent (or sildenafil) to GES-1 cells.

FIGs. 8A-8C depict an exemplary result of cell proliferative toxicity as determined after administration of a nitric oxide releasing agent (or sildenafil) to FHs 74 Int cells.

FIGs. 9A-9D depict the relative intracellular and extracellular NO levels of HUVEC and GES-1 cells.

FIGs. 10A-10D depict the relative extracellular NO levels after 24 hours of treatment with a nitric oxide releasing agent.

FIGs. 11A-11D depict the relative intracellular NO levels after 24 hours of treatment with a nitric oxide

releasing agent.

FIGs. 12A-12B depict the relative intracellular and extracellular NO levels at various time points after treatment of HUVEC cells with sildenafil.

FIGs. 12C-12D depict the relative intracellular and extracellular NO levels after 24 hours of treatment of HUVEC cells with sildenafil at various concentrations .

FIGs. 13A-13B depict the relative intracellular and extracellular NO levels after 24 hours of treatment GES-1 cells with 100 μ M sildenafil.

FIG. 13C-13D depict the relative extracellular and intracellular NO levels after 24 hours of treatment of HaCaT cells with 100 μ M sildenafil.

FIG. 14 depicts the photographs of left paw, front side, and right paw of rat model with hand-foot syndrome caused by VEGFR and/or VEGF inhibition.

FIG. 15 depicts the photographs of left paw, front side, and right paw of a typical rat (administered to the left paw) in the administration groups of examples 55-100 and 111-112 of the present application.

FIG. 16 depicts the photographs of left paw, front side, and right paw of a typical rat (administrated to the right paw) in the administration groups of examples 101-108 of the present application.

FIG. 17 depicts the photographs of left paw, front side, and right paw of a typical rat (administered to the left paw) in the administration groups of examples 113-123 of the present application.

FIG. 18 depicts the photographs of left paw, front side, and right paw of a typical rat (administered to the right paw) in the administration group of example 124 of the present application.

FIG. 19 depicts the effect of tumor volume change in a tumor-bearing rat which is treated with a VEGFR/VEGF inhibitor when the nitric oxide releasing agent of example 143 of the present application is external administered.

FIG. 20 depicts an exemplary result of cell proliferative toxicity as determined after administration of a nitric oxide releasing agent (or Diltiazem) to HUVEC cells.

FIG. 21 depicts an exemplary result of cell proliferative toxicity as determined after administration of a nitric oxide releasing agent (or calcium channel blocker) to HaCaT cells.

FIG. 22 depicts the relative NO levels after administration of a nitric oxide releasing agent (or calcium channel blocker) to HaCaT cells.

FIG. 23 depicts the expression level of Calmodulin (CaM) after administration of a nitric oxide releasing agent (or calcium channel blocker) to HaCaT cells.

FIG. 24 depicts the result of gray value analysis of the expression level of Calmodulin (CaM) after

administration of a nitric oxide releasing agent (or calcium channel blocker) to HaCaT cells.

FIG. 25 depicts the expression level of Calreticulin after administration of a nitric oxide releasing agent (or calcium channel blocker) to HaCaT cells.

FIG. 26 depicts the result of gray value analysis of the expression level of Calreticulin after administration of a nitric oxide releasing agent (or calcium channel blocker) to HaCaT cells.

FIG. 27 depicts the photographs of left paw, front side, and right paw of a typical rat (administrated to the left paw and right paw) in the administration groups of examples 148-153 of the present application.

FIG. 28 depicts the photographs of left paw, front side, and right paw of a typical rat (administrated to the left paw and right paw) in the administration groups of examples 154 of the present application.

DETAILED DESCRIPTION

The embodiments of the present application are described hereinafter by means of specific examples. Persons skilled in the art can readily understand the other advantages and effects of the inventions as described herein from the disclosure of the present specification.

VEGFR inhibitor and/or VEGF Inhibitor

As used herein, the term “VEGFR” generally refers to Vascular Endothelial Growth Factor Receptor which belongs to the Receptor tyrosine kinases (RTKs) family. It comprises primarily three subtypes, including VEGFR1, VEGFR2, and VEGFR3 as reported. Of those, VEGFR1, and VEGFR2 are primarily distributed on the surface of tumor vascular endothelium, regulating the tumor angiogenesis; and VEGFR3s is primarily distributed on the surface of lymph endothelium, regulating the tumor lymphangiogenesis. It is reported that VEGFR2s is the primary VEGF signal transduction receptors during the angiogenesis and mitosis processes. The VEGF family comprises primarily VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor (PGF). VEGF-A in combination with VEGFR-1 and VEGFR-2 can regulate almost all the cell responses to VEGF as reported. The activation of VEGFR-2 in endothelial cells results in increased proliferation, migration, survival and improved vascular permeability (see, Waldner, Maximilian J. et al., the Journal of Experimental Medicine 207.13, 2010). The expression of VEGFR or the increased kinase activity thereof is associated with a series of human cancers.

As used herein, the term “VEGF” generally refers to Vascular Endothelial Growth Factor which is known as the specific growth factor of the key endothelial cells required by pathological angiogenesis signal pathway according to reports. The inhibition of VEGF receptor tyrosine kinase signal pathway blocks the

angiogenesis during the growth of tumors, resulting in stagnation or regression of angiogenic tumors (see, Gerald McMahon, the Oncologist 2000, 5:3-10).

As used herein, the term “VEGFR inhibitor” generally refers to any substance or agent capable of causing the decreased expression, quantity or activity of VEGFR which is known in the art or may be discovered in the future, comprising any substance which may cause an inhibition of biological activity associated with VEGFR activity when the substance or agent is administered to a subject (including an inhibition of downstream biological effect produced by combination of any VEGFR with its natural ligand). In some embodiments, the VEGFR inhibitor may comprise any agent capable of blocking the VEGFR activity or any downstream biological effect thereof during the treatment of cancers. For instance, the VEGFR inhibitor may be used to treat tumors. For instance, the VEGFR inhibitor may inhibit one or more functions of VEGFR directly. For instance, the VEGFR inhibitor may combine with a nucleic acid sequence encoding VEGFR. For instance, the VEGFR inhibitor may reduce the transcription level of VEGFR protein.

As used herein, the term “VEGF inhibitor” generally refers to any substance or agent capable of causing the decreased expression, quantity or activity of VEGF which is known in the art or may be discovered in the future, comprising any substance which may cause an inhibition of biological activity associated with VEGF activity when the substance or agent is administered to a subject. In some embodiments, the VEGF inhibitor may comprise any agent capable of blocking the VEGF activity or any downstream biological effect thereof during the treatment of cancers. For instance, the VEGF inhibitor may be used to treat tumors. For instance, the VEGF inhibitor may inhibit one or more functions of VEGF directly. For instance, the VEGF inhibitor may combine with a nucleic acid sequence encoding VEGF. For instance, the VEGFR inhibitor may reduce the transcription level of VEGF protein.

As used herein, whatever in vitro or in vivo, the method of detecting and/or evaluating the inhibition level of the VEGF and/or VEGFR is normal in the art. And the method may be used in verify, standardize, screen and/or evaluate the VEGF inhibitor and/or VEGFR inhibitor of the present application.

As used herein, the term “disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor” generally refers to disease or disorder related to administrate VEGFR inhibitor and/or VEGF inhibitor to a subject. For instance, the disease or disorder may be disease or disorder caused by administering VEGFR inhibitor and/or VEGF inhibitor to a subject. For instance, the disease or disorder may comprise skin tissue disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, facial organ disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, and/or gastrointestinal disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF

inhibitor. For instance, the disease or disorder may comprise rash associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, pruritus associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, erythema associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerosis cutis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, alopecia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, paronychia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, pigmentation disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, oral mucositis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerostomia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, epistaxis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nasopharyngitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, cheilitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, esophagitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, gastric ulcer associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, diarrhea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, vomiting associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nausea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, anorexia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, constipation associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, and/or abdominal pain associated with administration of the VEGFR inhibitor and/or VEGF inhibitor. In present application, the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor may be hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor.

As used herein, the term “tumor” generally refers to neoformation formed by local tissue cell proliferation under the action of various tumorigenic factors, which is also known as neoplasm. According to the cellular properties of the neoformation and the harm extent to an organism, the tumors are in turn classified to two types, i.e., benign tumors and malignant tumors, and cancer is a general term for malignant tumors. The tumors may be selected from the group consisting of malignant epithelial malignant tumors (epithelium-derived cancers), lung cancer (e.g., non-small cell lung cancer), breast cancer, skin cancer, bladder cancer, colon cancer, bowel cancer, prostate cancer, pancreas cancer, uterine cancer, cervical cancer, ovarian cancer, esophagus cancer, head and neck cancer, stomach cancer and laryngeal cancer. For instance, the tumor may be liver cancer, kidney cancer, colorectal cancer, stomach cancer, esophageal cancer or thyroid cancer.

As used herein, the VEGFR inhibitor and/or the VEGF inhibitor may be identified or screened by a

method known in the art, e.g., by detecting the change of expression or activity of VEGFR and/or VEGF after administration of the candidate substance/agent. The expression of VEGFR and/or VEGF may also be detected by a method known in the prior art, e.g., an immunohistochemical method, PCR, RT-PCR, *in-situ* hybridization, Southern blot, Western blot, Northern blot, spectrophotometry, and ELISA, and the like.

As used herein, at least one (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more) of the VEGFR inhibitor may directly act on a VEGFR protein and/or a nucleic acid encoding a VEGFR protein.

As used herein, at least one (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more) of the VEGF inhibitor may directly act on a VEGF protein and/or a nucleic acid encoding a VEGF protein.

For instance, the VEGFR inhibitor may comprise a small molecular VEGFR inhibitor, a protein macromolecule specifically binding to VEGFR, an RNAi inhibiting the expression of a VEGFR protein and/or an antisense oligonucleotide inhibiting the expression of VEGFR protein.

As used herein, the term “small molecular VEGFR inhibitor” may comprise a small molecular VEGFR inhibitor reversibly or irreversibly binding to VEGFR or a small molecular VEGFR inhibitor specifically binding to a mutant VEGFR. For instance, the small molecular VEGFR inhibitor may comprise Regorafenib, Ponatinib, Cabozantinib, Lenvatinib, Sorafenib, Apatinib, Axitinib, Nintedanib, Vandetanib, Sunitinib, Midostaurin, Tivozanib, Fruquintinib, Cediranib, Brivanib, Donafenib, Sulfatinib, Anlotinib, Famitinib, Tesevatinib, Vorolanib, Motesanib, Linifanib, Semaxanib, Dovitinib, Orantinib, Vatalanib, Telatinib, Glesatinib, Lucitanib, Ilorasertib, Rebastinib, Golvatinib, Foretinib, Ningetinib, Tafetinib, Altiratinib, TAS-115, Chiauranib, Henatinib, 4SC-203, AAL-993, ACTB-1003, AEE-788, AMG-628, Arenobufagin, BAW2881, BIBF-1202, BMS-690514, BMS-794833, CEP-11981, CEP-5214, CP-547632, CYC116, DW532, ENMD-2076, FIIN-1, GFB-204, BFH-772, BMS599626, BMS690514, PP 121, MGCD 265 analogue, AC480, Ki 8751, KRN 633, WHI-P 154, TAK593, JI 101, AZD-2932, SCR-1481B1, Isoliquiritigenin, JNJ-26483327, KI-20227, LY2457546, ODM-203, OSI-930, PF-00337210, CGP41231, R1530, RAF265, SAR131675, Semaxinib, SIM010603, SKLB1002, SKLB610, SU 5205, SU11652, SU14813, SU-1498, SU-4312, SU5402, T-1840383, Tanshinone IIA, TAS-115, TG 100572, TG 100801, TG100572 HCl, Toceranib, Tyrosine phosphorylation inhibitor A9, Tesevatinib, XL-844, XL999, ZD4190 HCl, ZM-306416, ZM323881 HCl, ABT-510, NVP-ACC789, ADT-OH, BMS-645737, EG 00229, XL-820, SGI-7079, Endostatin and/or Taxifolin.

As used herein, the term “specifically binding” generally means that in a complicated mixture, the

VEGFR inhibitor may specifically recognize and bind to VEGFR, but does not substantially recognize or bind to other components in the complicated mixture. For instance, the affinity of the inhibitor to VEGFR may be at least 2 times the affinity of the inhibitor to other non-specific binding ingredients (e.g., at least 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times or more). In some embodiments, the equilibrium dissociate constant of the VEGFR inhibitor with VEGFR is less than or equal to 10^{-6} (e.g., less than or equal to 10^{-7} M, less than or equal to 10^{-8} M, less than or equal to 10^{-9} M, less than or equal to 10^{-10} M or less).

As used herein, the protein macromolecule that specifically binds to VEGFR may be an antibody, the antibody variant, fusion protein, derivative or a fragment thereof that targets VEGFR. For instance, it may be an antibody that specifically binds to VEGFR or a fragment of antigen binding thereof.

As used herein, the antibody generally refers to a polypeptide molecule capable of specifically recognizing and/or neutralizing a specific antigen. For instance, the antibody may comprise an immunoglobulin composed of at least two heavy (H) chains and two light (L) chains that are linked to each other via disulfide bond, and comprise any molecule containing an antigen binding fraction thereof. The term “antibody” may comprise a monoclonal antibody, an antibody fragment or an antibody derivative, including, but not limited to, a human antibody (full humanized antibody), a humanized antibody, a chimeric antibody, a single-stranded antibody (e.g., scFv), and an antibody fragment binding to an antigen (e.g., Fab, Fab' and (Fab)₂ fragment). Of those, the chimeric antibody may be an antibody in which a part of the amino acid sequence of each heavy chain or light chain is homologous to the corresponding amino acid sequence of an antibody derived from a species, or belongs to a particular classification, while the remainder segment of the chain is homologous to the corresponding sequence of another species. Of those, the humanized antibody may refer to a chimeric antibody which comprise a small amount of sequence derived from a non-human immunoglobulin, thereby decreasing the immunogenicity when a hetero-antibody is introduced into humans, but keeping a complete antigen binding affinity and specificity of the antibody. Of those, the full humanized antibody may comprise antibody produced by human or human immune cells, or derived from a non-human source (e.g., a genetically modified non-human animal by using a humanized antibody library), or other sequences encoding a human antibody.

As used herein, the fragment of antigen binding of an antibody may be one or more fragments having a specific antigen binding function. The antigen binding function of an antibody may be achieved by a full-length fragment of the antibody. The antigen binding function of the antibody may also be achieved by means of: a heavy chain containing Fv, ScFv, dsFv, Fab, Fab' or F(ab')₂ fragment, or a light chain containing

Fv, ScFv, dsFv, Fab, Fab' or F(ab')₂ fragment. (1) Fab fragment, that is a monovalent fragment composed of VL, VH, CL and CH domains; (2) F(ab')₂ fragment, that is a divalent fragment containing two Fab fragments linked by a disulfide bond in the hinge region; (3) Fd fragment composed of VH and CH domains; (4) Fv fragment composed of VL and VH domains of one arm of the antibody; (5) dAb fragment composed of VH domain (Ward et al., (1989) Nature 341: 544-546); (6) isolated complementary determining region (CDR); (7) a combination of two or more isolated CDRs that may be optionally linked via a linker; (8) Camelized single domain antibody, that is an antibody comprising two heavy chain variable regions but not containing light chain and (9) nanobody, comprising a heavy chain variable region, CH2 and CH3. Moreover, it may further comprise monovalent single-stranded molecule Fv (scFv) formed by pairing VL and VH (scFv) (see, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc.Natl.Acad.Sci. 85: 5879-5883). The term "portion of antigen binding" may further comprise an immunoglobulin fusion protein comprising binding domains selected from the group consisting of (1) a peptide of binding domain fused with a peptide of immunoglobulin hinge region; (2) a heavy chain CH2 constant region of Immunoglobulin fused with a hinge region; and (3) a heavy chain CH3 constant region of immunoglobulin fused with a CH2 constant region.

For instance, the protein macromolecule that specifically binds to VEGFR may be Ramucirumab, a fragment of antigen binding or a functional variant thereof.

As used herein, the term "VEGF trapping agent" generally refers to an agent capable of trapping VEGF by binding thereof. For instance, the VEGF trapping agent may be selected from the group consisting of Bevacizumab and Aflibercept.

As used herein, the term "an agent of reducing the expression of VEGF" generally refers to a substance capable of directly or indirectly decreasing the expression of VEGF in a subject. For instance, the agent of reducing the expression of VEGF may be selected from the group consisting of Temsirolimus and Thalidomide.

As used herein, the term "RNAi" generally refers to RNA interference, which is generally an exogenous or endogenous double-stranded RNA molecule or a small molecular RNA, and typically inhibits the expression or translation of a target gene through the specific degradation of RNAi caused by targeting mRNA. In general, RNAi comprises two types of small molecular RNAs: microRNA (miRNA) and small interference RNA (siRNA), which are capable of binding to other mRNA molecules, thereby increasing or decreasing the activity thereof, e.g., preventing mRNA from being translated to protein. In an eukaryotic animal, RNAi path cleaves a long double-stranded RNA (dsRNA) by RNaseIII enzyme (e.g., Dicer, DCL or Drosha) to double-stranded siRNA fragments having about 20-23 nucleotides in length. Each siRNA is resolved to two

single-stranded RNAs (ssRNA), i.e., a passenger chain and a guide chain. The passenger chain is degraded, while the guide chain is integrated into an RNA inducing silencing complex (RISC). When the guide chain is complementary to an mRNA molecule, the RISC cleaves the mRNA molecule, thereby resulting in the degradation of the mRNA molecule.

As used herein, an RNAi that inhibits the expression of a VEGFR protein may inhibit the expression or translation of VEGFR by targeting a mRNA encoding VEGFR so as to specifically degrading the mRNA. As used herein, the RNAi inhibiting the expression of VEGF protein may inhibit the expression or translation of VEGF by targeting an mRNA encoding VEGF so as to specifically degrading the mRNA.

As used herein, the term “oligonucleotide” generally refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or any mimic thereof or structurally modified nucleic acid. The term comprises oligonucleotides consisting of naturally occurring nucleobases, pentose and covalent nucleoside (backbone), and non-naturally occurring oligonucleotides having similar function. The modified or substituted oligonucleotide is generally superior to the naturally occurring forms as they have, e.g. increased cell uptake, increased affinity to target nucleic acid, and increased stability in the presence of nuclease.

As used herein, the term “antisense oligonucleotide” generally refers to a single-stranded oligonucleotide having nucleobase sequence that may at least partially hybridize with the corresponding region or fragment of the target nucleic acid. As used herein, the antisense oligonucleotide may comprise about 8 to about 50 nucleobases.

As used herein, the VEGFR inhibitor is capable of inhibiting VEGFR1, VEGFR2 and/or VEGFR3. For instance, the VEGFR inhibitor is capable of inhibiting one, two or three of VEGFR1, VEGFR2, and VEGFR3.

In some embodiments, the VEGFR inhibitor may comprise Ramucirumab, Bevacizumab, Regorafenib, Ponatinib, Cabozantinib, Lenvatinib, Sorafenib, Pazopanib, Apatinib, Axitinib, Nintedanib, Vandetanib, Sunitinib, Midostaurin, Tivozanib, Fruquintinib, Cediranib, Brivanib, Donafenib, Sulfatinib, Anlotinib, Famitinib, Tesevatinib, Vorolanib, Motesanib, Linifanib, Semaxanib, Dovitinib, Orantinib, Vatalanib, Telatinib, Glesatinib, Lucitanib, Ilorasertib, Rebastinib, Golvatinib, Foretinib, Ningetinib, Tafetinib, Altiratinib, TAS-115, Chiauranib, Henatinib, 4SC-203, AAL-993, ACTB-1003, AEE-788, AMG-628, arenobufagin, BAW2881, BIBF-1202, BMS-690514, BMS-794833, CEP-11981, CEP-5214, CP-547632, CYC116, DW532, ENMD-2076, FIIN-1, GFB-204, BFH-772, BMS599626, BMS690514, PP 121, MGCD 265 analogue, AC480, Ki 8751, KRN 633, WHI-P 154, TAK593, JI 101, AZD-2932, SCR-1481B1, Isoliquiritigenin, JNJ-26483327, KI-20227, LY2457546, ODM-203, OSI-930, PF-00337210, CGP41231, R1530, RAF265, SAR131675, Semaxinib, SIM010603, SKLB1002, SKLB610, SU 5205, SU11652, SU14813, SU-1498, SU-4312, SU5402,

T-1840383, tanshinone IIA, TAS-115, TG 100572, TG 100801, TG100572 HCl, Toceranib, Tyrosine phosphorylation inhibitor A9, Tesevatinib, XL-844, XL999, ZD4190 HCl, ZM-306416, ZM323881 HCl, ABT-510, NVP-ACC789, ADT-OH, BMS-645737, EG 00229, XL-820, SGI-7079, Endostatin, Taxifolin, Afibercept, and/or a pharmaceutically acceptable salt of the VEGFR inhibitor and/or VEGF inhibitor above.

As used herein, the term “pharmaceutically acceptable salt” may refer to a pharmaceutically acceptable salt of the compound. In some embodiments, the pharmaceutically acceptable salt may be selected from the group consisting of Sorafenib tosylate, Sunitinib malate, Pazopanib hydrochloride, and Dovitinib (TKI258) lactate.

As used herein, the VEGFR inhibitor and/or the VEGF inhibitor may be administered in combination with one or more additional therapies. In some embodiments, the one or more additional therapies may comprise one or more additional anti-tumor therapy. For instance, the additional anti-tumor therapy may comprise cytotoxic anticancer agents, immunotherapeutic anticancer agents, or hormonotherapeutic anticancer agents. The additional anti-tumor therapies may further comprise radiotherapy or surgery therapy.

As used herein, when a VEGFR inhibitor and/or a VEGF inhibitor is administered in combination with additional anti-tumor therapies, they may be simultaneously administered to a subject or individually administered at intervals. For instance, the additional anti-tumor therapy may be a part of a single dosage form, and mixed with the VEGFR inhibitor and/or the VEGF inhibitor to form a single composition. As another example, the additional anti-tumor therapy may be a separate agent, which is administered separately from the VEGFR inhibitor and/or the VEGF inhibitor. As used herein, if the additional anti-tumor therapy and the VEGFR inhibitor and/or the VEGF inhibitor form a single composition, the VEGFR inhibitor and/or the VEGF inhibitor may be present and/or administered at a level of about 1-99% (e.g., about 5-95%, about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or about 99%) in relation to the total dosage.

Cytotoxic anticancer agents used in treating cancer may comprise alkylating agents such as chlormethine, nitrogen mustard N-oxide hydrochloride, Chloroambucil, Cyclophosphamide, Ifosfamide, thiotepa, isothiocyanate, Busulfan, Nimustine hydrochloride, mitropium bromide, Melphalan, Dacarbazine, Ranimustine, promethamine sodium phosphate, Diethylenetriamine, Carmustine, Lomustine, Streptozotocin, pipobroman, ethoglucid, Carboplatin, Cisplatin, Miriplatin, Nedaplatin, tenetamide, omustine, dichloropyridine, prednimustine, pumitepa, Ribomustin, Temozolomide, diclofenac, trovafloxacin, zinstatin, simvastatin, penems, cystemustine and bizelesin; antimetabolite such as mercaptopurine, 6-mercaptopurine glycoside, 6-thioinosine, methotrexate, pemetrexed, vortioxetine,

cytarabine, oxaliplatin, tizanidine hydrochloride, 5-FU and derivant of like (such as, fluorouracil, tegafur, UFT, Doxycycline, carmofur, capecitabine, etc); antitumor antibiotic such as actinomycin D, actinomycin C, mitomycin, Chromomycin A3, Bleomycin hydrochloride, Bleomycin, cetimycin hydrochloride, Doxorubicin hydrochloride, Mitoxantrone hydrochloride and Idarubicin hydrochloride; and/or, plant-derived cytotoxic anticancer drugs such as Etoposide, Etoposide phosphate, Vinblastine sulfate, Vincristine sulfate, Teniposide, paclitaxel, paclitaxel and vinorelbine and of like; VEGF inhibitor such as Bevacizumab, and those VEGF inhibitor disclosed at PCT patent application WO 2005/012359, WO 2005/044853, WO 98/45332, WO 96/30046, WO 94/10202, US Patent 7,060,269, US6,582,959, US6,703,020, US6,054,297, U.S. patent application US2006/009360, US2005/0186208, US2003/0206899, US2003/0190317, US2003/0203409 and US2005/0112126.

Immunotherapy agent used to treat cancer may comprise bubinini, Crestine, Benzofurazan, Lentinan, Ubenimex, Interferon, Interleukin, macrophage colony-stimulating factor, granulocyte colony-stimulating factor, Erythropoietin, lymphotoxin, BCG, *Corynebacterium Parvum*, everolimus, levamisole, PolysaccharideK, procodazole and/or immune checkpoint inhibitor (such as CTLA4 inhibitor, TIM-3 inhibitor, PD-1 inhibitor (such as, Nivolumab, Pembrolizumab, Pidilizumab, AMP514 (Amplimmune), AMP-224, and other PD-1 inhibitors disclosed PCT patent application WO2006/121168, WO2009/114335, WO2009/101611, U.S. patent US 8609089, U.S. patent application US2010/028330, US2012/0114649), PD-L1 inhibitor (such as, YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, MDX-1105, and other PD-L1 inhibitors disclosed in PCT patent application WO2010/077634 and U.S. patent US7,943,743)).

Hormonotherapeutic anti-cancer agent used in treating cancer may comprise urinastatin, diethylstilbestrol, chlorinated costen, medroxyprogesterone acetate, Megestrol acetate, cyproterone acetate, cyproterone acetate, danazol, allylestrenol, progesterone, mepartricin, Raloxifene, Levofloxacin, antiestrogen (such as, Tamoxifen citrate salt, toremifene citrate salt and of like), contraceptive pill, prostacyclin, testolactone, amino succinimide, LH-RH agonist (such as, goserelin acetate, buserelin, leuporelin and of like), droloxifene, epiandrosterone, ethinylestradiol sulfonate, flubendazole hydrochloride, anastrozole, letrozole, exemestane, vorozole, anti-androgens (such as, flutamide, bicalutamide, nilutamide and of like), 5 α - statin (such as, finasteride, epristeride), corticosteroid (such as, Dexamethasone, Prednisolone, Betamethasone, Triamcinolone acetonide and of like) and/or androgen antagonists (such as, abiraterone and of like).

VEGFR and/or VEGF inhibition-associated disease or disorder

As used herein, the disease or disorder associated with administration of the VEGFR inhibitor and/or

VEGF inhibitor may be statistically significantly associated with the VEGFR and/or VEGF inhibition. In some embodiments, the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor is caused by the VEGFR and/or VEGF inhibition. For instance, the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor may comprise skin tissue disease or disorder, facial organ disease or disorder and/or gastrointestinal disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor. For instance, the skin tissue disease or disorder, facial organ disease or disorder and/or gastrointestinal disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor may comprise a epithelial disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor in skin tissue, facial organ and/or gastrointestinal tract. In some embodiments, the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor comprises side effects or adverse reactions caused by the VEGFR inhibitor and/or the VEGF inhibitor.

As used herein, the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor may be a new indication that may be different from any other disease or disorder of the past. For instance, the diagnostic methods, treatment methods and/or symptoms of the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor are all unique. For instance, erythromycin ointment is capable of treating rash, while has no effect on treating the rash associated with administration of the VEGFR inhibitor and/or VEGF inhibitor.

As used herein, the term “skin tissue disease or disorder” generally refers to the pathologic changes occurred in the morphology, structure and/or function of skin (including hair and nail). For instance, the skin tissue disease or disorder may comprise, but is not limited to rash, hand-foot syndrome, pruritus, erythema, xerosis cutis, alopecia, paronychia, pigmentation disorder, and the like.

As used herein, the term “rash” generally refers to a skin change capable of affecting the color, appearance, or texture of skin. Rash may be localized to only a portion of the body, or affect the overall skin.

Rash further comprises urticaria.

As used herein, the term “hand-foot syndrome” is also known as Hand Foot Syndrome (HFS), or Palmar Plantar Erythrodysesthesia (PPE) , or Hand-foot skin reaction (HFSR) , which was first described in 1984 by Jacob Lokich and Cery Moor of New England Diaconis Hospital of Harvard Medical School. The typical clinical manifestations are progressive. The primary clinical manifestations comprise finger (toe) fever, pain, erythematous swelling, serious person for desquamation, ulcer, and severe pain, etc. The pathologic manifestations of HFS primarily comprise, e.g., basal keratinocyte vacuolar degeneration, skin perivascular

lymphocyte infiltration, keratinocyte apoptosis, and skin edema, and the like. For instance, HFS may comprise palmar or plantar dysesthesia, or acral erythema caused by chemotherapy, or the like. Cancer patients may develop the corresponding symptoms during the process of chemotherapy or molecular targeted therapy (e.g., the VEGFR inhibitor and/or the VEGF inhibitor).

Currently, there are a variety of classification methods for hand-foot syndrome (HFS), wherein the criterion of the American National Cancer Institute (NCI) is relatively common used. This criterion classifies the hand-foot syndrome as 3 Grades: Grade 1 is minimal skin changes or dermatitis with paresthesia (e.g., fingerprints disappearance, pigmentation, erythema, decrustation, paresthesia, dysesthesia, skin numbness, etc.), but does not affect daily activities; Grade 2 is the same level of skin change as Grade 1 with pain, slightly affects daily activities, and the skin surface is intact; and Grade 3 is ulcerative dermatitis or serious painful cutaneous lesions, seriously affects daily life, and has obvious tissue damage (e.g., desquamation, blisters, hemorrhage, edema, etc.).

Moreover, the World Health Organization (WHO) classifies HFS as four grades: Grade 1 is a feeling of dysesthesia, paresthesia, or tingling in the hands and feet; Grade 2 is discomfort when holding objects and walking, painless swelling, or erythema; Grade 3 is painful erythema and swelling of palms and soles, periungual erythema and swelling; and Grade 4 is decrustation, ulceration, blistering and severe pain.

As used herein, the term “erythema” generally refers to local or systemic red maculae caused by localized or systemic expansion of dermal papillary capillary network.

As used herein, the term “paronychia” generally refers to an infectious lesion of soft tissues around finger (toe) nails, which is generally caused by subcutaneous invasion and reproduction of bacteria through slight skin damage near the nails, and has clinical manifestations including painful redness and swelling of the affected area, with inflammatory exudation, and granulation tissue proliferation, etc.

As used herein, the term “pigmentation disorder” generally refers to a disorder in which the skin exhibits a lighter or darker color as compared with normal conditions, produces stains, or discolors. Hypopigmentation is due to the insufficiently production of pigments in the body, while hyperpigmentation is due to the excess production of pigments in the body.

As used herein, the term “facial organ disease or disorder” generally refers to a pathologic change occurred in the morphology, structure, and/or function of organs including ears, eyebrows, eyes, nose, mouth, etc. For instance, the facial organ disease or disorder may comprise but are not limited to oral Mucositis, xerostomia (dry mouth), epistaxis, nasopharyngitis and/or cheilitis.

As used herein, the term “nasopharyngitis” generally refers to inflammatory reactions of nasopharyngeal

mucosa, submucosa and lymphoid tissues, and may be classified to acute nasopharyngitis and chronic nasopharyngitis. Symptoms comprise, but are not limited to, nasopharyngeal dryness and discomfort, sticky secretions different to be coughed up, and are often accompanied with nausea, severe cases of hoarseness, sore throat, headache, dizziness, fatigue, indigestion, hypothermia, as well as other local or systemic symptoms.

Nasopharyngeal examination shows chronic mucosa congestion, hyperplasia, hypertrophy, secretion covering or dry scab, etc.

As used herein, the term “cheilitis” generally refers to inflammatory disease or disorder occurring in lips. For instance, it may comprise inflammations of perioral skin, vermilion border, and/or buccal mucosa, and the like. It may be classified into: acute cheilitis and chronic cheilitis, according to the course of disease; erosive cheilitis, eczematous cheilitis, desquamative cheilitis, according to the clinic symptom characteristics; and chronic non-specific cheilitis, cheilitis glandularis, cheilitis of benign lymph adenosis, cheilitis granulomatosa, Melkersson-Rosenthal Syndrome, actinic cheilitis and allergic cheilitis, etc., according to the etiology and pathology.

As used herein, the term “gastrointestinal disease or disorder” generally refers to the pathological change of morphology, structure and/or function of gastric or intestinal tissues (e.g., digestive tract tissues from gastric pylorus to anus). For instance, the gastrointestinal disease or disorder may comprise, but is not limited to, diarrhea, vomiting, nausea, anorexia, constipation and/or abdominal pain, and the like.

As used herein, the VEGFR inhibitor and/or VEGF inhibitor may be used to treat tumor. For instance, the location of the disease or disorder is different from that of tumor.

As used herein, the skin tissue disease or disorder, facial organ disease or disorder and/or gastrointestinal disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, may comprise epithelial disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor in the skin tissue, facial organ and/or gastrointestinal tract.

As used herein, the term “epithelial tissue” comprises one or more layers of free and surface-closed cells covering the whole body, comprising, skin, mucus, cavity, slurry and gland spaces. All the epithelial layers comprise two special domains, that is, the top domain facing the mucus (or cavity) space and the basolateral membrane facing the serosal (or deep) space. Thus, an important function of epithelial tissues is to provide a proper barrier to separate and control a variety of physiological processes between the two spaces. The epithelial tissue comprises epithelial cells and endothelial cells.

As used herein, the term “epithelial disease or disorder” generally refers to disease or disorder caused by lesion of epithelial cell and/or endothelial cell. For instance, the epithelial disease or disorder may comprise

rash, acne, skin pruritus, alopecia, hair change, erythema, skin exfoliation, herpes, hirsutism, hyper-pigmentation, nail disorders, paronychia and schizonychia, xerosis cutis, hypersensitivity, mucositis, nasopharyngitis, xerostomia, cheilitis, oral mucositis and/or gastrointestinal mucosal injury. As another example, the epithelial disease or disorder may also comprise skin epithelial cell disease or disorder (e.g., rash, acne, rosacea, atopic dermatitis, contact dermatitis, seborrheic dermatitis, lupus, scleroderma, pemphigus, pigmentation, black spot, leukoderma, urticaria, tinea corporis, the skin pruritus, alopecia, hair change, erythema, paronychia and schizonychia, xerosis cutis, hypersensitivity and psoriasis), oral epithelial cell disease or disorder (e.g., pemphigus, herpes labialis, herpetic stomatitis, granulomatous cheilitis, oral mucositis, pemphigoid, xerostomia syndrome, Bechet disease and oral sarcoidosis, etc.), nasal epithelial cell disease or disorder (epistaxis, sinusitis, nasal furuncle and nasal polyps, etc.), stomach epithelial cell diseases or disorders (e.g., gastritis, intestinal metaplasia, gastric perforation, gastric fistula, gastric ulcer and gastrointestinal polyp) and/or small intestine epithelial cell disease or disorder (e.g., enteritis, Crohn's disease, enterobrosis, intestinal fistula, enterelcosis, ulcerative colitis and NSAIDs bowel disease).

As used herein, the epithelial disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor may comprise the disease or disorder associated with lesion of endothelia cell, and/or the disease or disorder associated with epithelial cell lesion, wherein the lesion of endothelia cell and/or epithelial are associated with the VEGFR and/or VEGF inhibition.

For instance, the endothelial cells may comprise vascular endothelial cell. The lesion of vascular endothelial cell may comprise endothelia dysfunction. For instance, the lesion of vascular endothelia cell may comprise degenerative vascular disease (e.g., atherosclerosis, media arteriosclerosis and arteriolosclerosis (e.g., habitative arteriolosclerosis and proliferative arteriolosclerosis)), inflammatory vascular disease (e.g., infectious arteritis, arteritis syphilitica, giant cell arteritis, thromboangitis obliterans and rheumatic arteritis), functional vascular disease (e.g., Raynaud's disease, acrocyanosis and erythema acrodynia) and congenital vascular disease (e.g., congenital arteriovenous fistula) and the like.

As used herein, the epithelial cell may comprise skin epithelial cell, oral epithelial cell, nasal epithelial cell, gastric epithelial cell and/or intestinal epithelial cell. For instance, the lesion of epithelial cell may comprise lesion of skin epithelial cell (e.g., rash, acne, rosacea, atopic dermatitis, contact dermatitis, seborrheic dermatitis, lupus, scleroderma, pemphigus, pigmentation, black spot, leukoderma, urticaria, tinea corporis, the skin pruritus, alopecia, hair change, erythema, paronychia and schizonychia, xerosis cutis, hypersensitivity and psoriasis), lesion of oral epithelial cell (e.g., pemphigus, herpes labialis, herpetic stomatitis, granulomatous cheilitis, oral mucositis, pemphigoid, xerostomia syndrome, Bechet disease and oral sarcoidosis, etc.), lesion

of nasal epithelial cell (epistaxis, sinusitis, nasal furuncle and nasal polyps, etc.), lesion of gastric epithelial cell (e.g., gastritis, intestinal metaplasia, gastric perforation, gastric fistula, gastric ulcer and gastrointestinal polyp) and/or lesion of small intestine epithelial cell (e.g., enteritis, Crohn's disease, enterobrosis, intestinal fistula, enterelcosis, ulcerative colitis and NSAIDs bowel disease).

5 It is found by the inventor that the inhibition of VEGFR and/or VEGF may cause injury of endothelial cell, and endothelial tissue, thereby causing the disease or disorder of skin tissue, oral tissue, nasal tissue and/or gastrointestinal tissue. During the occurring and development of these disease or disorder, the course of disease generally begins with the injury/lesion of endothelial cell and endothelia tissue, together with the lesion symptoms of epithelial cell, and finally presents as endothelia cell lesion associated with administration
0 of the VEGFR inhibitor and/or VEGF inhibitor, and/or epithelial cell lesion associated with administration of the VEGFR inhibitor and/or VEGF inhibitor in a patient.

In some embodiments, the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor may comprise a rash associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF
5 inhibitor, pruritus associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, erythema associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerosis cutis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, alopecia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, paronychia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, pigmentation disorder associated with administration of the VEGFR inhibitor and/or
10 VEGF inhibitor, oral mucositis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerostomia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, epistaxis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nasopharyngitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, cheilitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, esophagitis associated with administration of the VEGFR inhibitor and/or VEGF
25 inhibitor, esogastritis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, gastric ulcer associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, diarrhea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, vomiting associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nausea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, anorexia associated with administration of the VEGFR inhibitor and/or VEGF
30 inhibitor, constipation associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, and/or, abdominal pain associated with administration of the VEGFR inhibitor and/or VEGF

inhibitor. For instance, disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor comprise hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor. For instance, the severity of hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor is Grade 1 or above, Grade 2 or above, Grade 3 or above, Grade 4 or above, and/or Grade 5 or above according to NCI-CTCAE V5.0.

In some embodiments, the disease or disorder may comprise rash, hand-foot syndrome, pruritus, erythema, xerosis cutis, alopecia, paronychia, pigmentation disorder, oral mucositis, xerostomia, epistaxis, nasopharyngitis, cheilitis, esophagitis, esogastitis, gastric ulcer, diarrhea, vomiting, nausea, anorexia, constipation, and/or, abdominal pain. For instance, the disease or disorder comprises hand-foot syndrome.

In some embodiments, the VEGFR and/or VEGF inhibition-associated disease or disorder cannot substantially be treated or ameliorated by administration of an agent selected from the group consisting of: 1% sildenafil, urea frost, Vaseline ointment, urea ointment, brimonidine ointment, vitamin B6 ointment, nicotine ointment, dexamethasone ointment, hydrocortisone ointment, Vkl ointment (0.1%), erythrosine ointment and triamcinolone ointment.

Nitric Oxide Releasing Agent

As used herein, the term “the nitric oxide releasing agent” generally refers to any substance capable of contributing to, producing and/or releasing nitric oxide. In some embodiments, the nitric oxide releasing agent may directly contribute to, produce and/or release nitric oxide. For instance, the nitric oxide releasing agent may stimulate other substances so as to contribute to, produce and/or release nitric oxide. For instance, the nitric oxide releasing agent serves as a reactant of a chemical or enzyme-catalyzed reaction and contributes to, produces and/or releases nitric oxide via such reaction. In some embodiments, the nitric oxide releasing agent serves a catalyst of a chemical or enzyme-catalyzed reaction, and stimulates other substances to contribute to, produce and/or release nitric oxide via such reaction. The nitric oxide releasing agent may comprises nitric oxide itself.

The nitric oxide releasing agents may be identified or screened by methods well known in the art, e.g., it is possible to detect the ability of the compound to be tested for contributing, producing, releasing and/or directly or indirectly transferring nitric oxide by detecting the levels of nitrite, NO, NO²⁻ and/or S-nitroso thiol. Any method known in the art may be used to detect the level of nitrite, NO, NO²⁻ and/or S-nitroso thiol. For instance, the nitric oxide releasing agents may be identified or screened by detecting nitrite, e.g., analyzing nitrite by Griess Analysis (Molecular Probes), which is on the basis of the reaction between nitrite and

para-amino benzenesulfonic acid, followed by detecting the reaction product via spectrophotometry. It is also possible to carry out the measurement by reducing nitrite/nitrate to NO in a reflux chamber at 95°C by a highly sensitive chemiluminescence technology. As another example, it is possible to identify or screen the nitric oxide releasing agents by detecting the Hb-NO level in blood. It is known that NO binds closely to hemoglobin (Hb), and the interaction between NO and Hb is known as the primary pathway of NO metabolism in blood vessels. Thus, the Hb-NO level in blood is a good indicator of the endogenous production of NO. In some embodiments, it is possible to determine the paramagnetic hemoglobin-NO adduct (Hb-NO) in the whole blood and the erythrocytes by electron paramagnetic response (EPR) spectroscopy so as to identify or screen the nitric oxide releasing agents. As another example, it is possible to identify or screen the nitric oxide releasing agents by amperometry of NO-specific electrode. This method requires inserting a NO electrode into the living body or sample. As another example, it is possible to identify or screen the nitric oxide releasing agents by detecting S-nitroso thiol. In Eco Medics CLD 88 Exhalyzer (Annex, Herts, UK), the S-nitroso thiol of a protein is measured by using chemiluminescence detection (Feelisch, M. et al., Concomitant S-, N-, and heme-nitros(yl)ation in biological tissues and fluids: implications for the fate of NO *in vivo*. FASEB. J 16, 1775-85 (2002)). As another example, it is possible to indirectly detect the NO level so as to identify or screen the nitric oxide releasing agents. For instance, an EndoPAT method is used to perform a non-invasive endothelial function detection to measure the NO level. The particular detection method may be found in U.S. Patent US9696324. It is also possible to indicate the NO level in serum by means of specifically reducing NO₃⁻ to NO₂⁻ by using a nitrate reductase, reacting NO₂⁻ with a chromogenic agent to generate a colored substance, and measuring the absorbance, thereby identifying or screening the nitric oxide releasing agents.

As used herein, the nitric oxide releasing agent is capable of producing at least one of NO⁺, NO[•], N₂O, NO, N₂O₃, NO₂, NO₃⁻ and NO₂⁻. For instance, the nitric oxide releasing agent is capable of directly or indirectly producing NO.

As used herein, the nitric oxide releasing agent may comprise an organic molecule, an inorganic molecule, a macromolecule, a nanomaterial, and/or an Ammonia Oxidizing Microorganism (AOM). For instance, the nitric oxide releasing agent may be NO.

As used herein, the item “organic molecular” generally refer to compound comprising carbon element, and not comprising oxide of carbon, carbonic acid, carbonate, cyanogen, cyanide, oxocyanide, cyanate, thiocyanogen, metal carbide and of like.

For instance, the nitric oxide releasing agent may comprise organic molecules, and the organic molecules may comprise nitroglycerin, isosorbide mononitrate, pentaerythritol tetranitrate, isosorbide dinitrate, trolnitrate,

Nicorandil, propatyl nitrate, Molsidomine, 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazole, isoamyl nitrite, 3,3-di(aminoethyl)-1-hydroxyl-2-carbonyl-1-triazene (NOC-18), sulfa nucleophilic complex disodium salt, S-nitroso glutathione, S-nitroso-N-acetyl penicillamine, 4-phenyl-3-furonitrile, (±)-(E)-4-Ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide, streptozocin, NG-Hydroxy-L-arginine acetate salt, O₂-(2,4-Dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diolate, N-nitrosodibutylamine, 3-morpholino-sydnnonimine, linsidomine, 3-(4-acetylphenyl) sydnnone, diethylamine nucleophilic complex /AM, and/or Itramin. For instance, the nitric oxide releasing agent may comprise organic molecules, and the organic molecules may comprise nitroglycerin, isosorbide mononitrate, and/or isosorbide dinitrate. In some embodiments, the organic molecules may comprise nitroglycerin.

As used herein, the nitric oxide releasing agent may comprise inorganic molecule, and the inorganic molecule may comprise nitril complex, nitrosyl complex, metal nitrosamine complex, nitrate and/or nitrite. For instance, the inorganic molecule may comprise sodium nitroprusside.

As used herein, the nitric oxide releasing agent may have a relative molecular weight of 2000 Daltons or below, 1500 Daltons or below, 1200 Daltons or below, 1000 Daltons or below, 900 Daltons or below, 800 Daltons or below, 700 Daltons or below, 600 Daltons or below, 500 Daltons or below, 400 Daltons or below, 300 Daltons or below, 200 Daltons or below, or 100 Daltons or below.

As used herein, the nitric oxide releasing agent may be a polymer comprising NO-donating groups. Any suitable polymer may be used, including crosslinked or uncross linked polymer, dendritic polymer, metal compound, organic metal compound, inorganic compound and other polymer scaffolds. The NO-releasing polymers may comprise, NO-releasing co-condensation silica, such as, diazoxide disulfate-functionalized polysiloxanepolyciliate, NO-releasing zeolite (see, U.S. Patent Application US2006/0269620 or US2010/0331968), NO-releasing metal organic framework (MOF) (see, U.S. Patent Application US2010/0239512 or US2011/0052650), NO-releasing multi-donor compound (see, U.S. Patent Application US2014/0171395), NO-releasing dendritic polymer or metal structure (see, U.S. Patent Application US2009/0214618), NO-releasing coating (see, U.S. Patent Application US2011/0086234), and the compounds described in U.S. Patent Application US2010/0098733 and PCT Patent Application WO2012/100174, the disclosure of which are hereby incorporated by reference in their entirety. In some embodiments, the nitric oxide releasing agent is a nanomaterial containing NO-donating group (s), e.g., nanocrystal that is a co-condensation siloxane network formed by silicon dioxide.

As another example, the NO-releasing polymer may further comprise S-nitrosothiol silica nanospheres, S-nitrosoethanedithiol chitin, oligopropylenediamine-grafted chitosan nitric oxide/nucleophile complexes

and/or the nitric oxide releasing agents manufactured by Novan Inc. (e.g., SB204, SB206, SB208, SB414 or NVN3100) and those disclosed in U.S. Patent US8,282,967, US8,956,658, US8,962,029, US9,403,851, US9,403,852, US9,187,501, US8,399,005, US8,981,139, US9,713,652, US9,238,038, US9,669,041, US8,591,876, US9,526,738, US9,737,561, US9,427,605, U.S. Patent Application US2009/0214618, 5 US2012/0021055, US2012/0034169, US2014/0005426, US2014/0058124, US2015/0182543, US2016/0060279, US2014/0065200, US2015/0225488, US2010/0297200, US2013/0196951, US2013/0344334, US2014/0017121, US2011/0086234, US2014/0134321, US2010/0098733, US2012/0230921, US2014/0171395, US2016/0083339, US2016/0199295, US2014/0255318, US2017/0246205, US2012/0136323, US2012/0156163, US2014/0057001, US2012/0134951, 0 US2017/0056437, US2017/0312307, US2017/0216197, US2015/0024052, US2008/0311163, US2016/0256366, US2015/0111973, US2017/0196905, PCT Patent Application WO2017/079268, WO2004/009253, WO2017/151905, WO2016/160089 and WO2017/019614.

As used herein, oligopropylenediamine-grafted chitosan nucleophile complex may comprise diazeniumdiolate. For instance, a nitric oxide releasing agent may be oligopropylenediamine-grafted chitosan 5 NONOate. As used herein, NONOate may comprise a chemical compound with a structure of $R^1R^2N-(NO-)-N=O$, wherein, R^1 and R^2 are both alkyls.

As used herein, the nitric oxide releasing agent may comprise ammonia oxidizing microorganisms (AOM), and the ammonia oxidizing microorganisms (AOM) may comprise ammonia oxidizing bacteria (AOB). For instance, the ammonia oxidizing microorganisms (AOM) may comprise *Nitrosomonas*, 0 *Nitrosococcus*, *Nitrosospira*, *Nitrosocystis*, *Nitrosolobus* and/or *Nitrosovibrio*. For instance, the ammonia oxidizing microorganisms (AOM) may comprise AOBiome, microbiota releasing NO of LLC (such as AOB101, AOB102, AOB103, AOB201, AOB201 or AOB203), and those disclosed in U.S. patent US7820420B2, US9738870B2, WO2017004534A2, US10078054B2, US2017189454A1, US20170191109A1, US20180092948A1, WO2018057710A1, WO2018017583A1, WO2018111888A1, US20070148136A1, 25 US2005106126A1, US20170037363A1, CN1997731A, US20170189454A1 and WO2017004557A1.

As used herein, the term “polymer” generally mean that any compound with a molecular weight of greater than 2000 Daltons, greater than 3000 Daltons, greater than 4000 Daltons, greater than 5000 Daltons, greater than 6000 Daltons, greater than 7000 Daltons, greater than 8000 Daltons, greater than 9000 Daltons, greater than 10000 Daltons, greater than 12000 Daltons, greater than 15000 Daltons or greater than 20000 30 Daltons.

As used herein, the term “small molecule” generally means that any compound with a molecular weight

of 2000 Daltons or less, 1500 Daltons or less, 1200 Daltons or less, 1000 Daltons or less, 900 Daltons or less, 800 Daltons or less, 700 Daltons or less, 600 Daltons or less, 500 Daltons or less, 400 Daltons or less, 300 Daltons or less, 200 Daltons or less or 100 Daltons or less.

As used herein, the nitric oxide releasing agent may have one or more groups as follow: diazeniumdiolate, hydroxyldiazenesulfonic acid, S-nitrosothiol, furoxan, oxime, N-nitrosoamine, N-hydroxylguanidine, diazeniumdiolate, nitrate, nitrite, nitrate ester, nitrite ester, sydnonimine, sydnone, oxatriazol-5-imine, oxatriazol-5-one, hydroxylamine, dioxadiazacyclobutene, N-hydroxynitrosoamine, N-nitrosoimine, hydroxycarbamide and metal nitrosamino complex.

For instance, the nitric oxide releasing agent may has one or more groups selected from Table 1:

Table 1

NO.	Compound	Structure of compound	Description
1	Diazeniumdiolate		Of those, R、R1、R2 may be organic chemical groups; M may be metal cation; X may be inorganic anion; a、b、n may be positive integer.
2	Diazeniumdiolate ester		
3	Hydroxyldiazenesulfonic acid		
4	S-nitrosothiol		
5	Furoxan		
6	Oxime		
7	N-nitrosoamine		
8	N-hydroxylguanidine		

9	Nitrate		
10	Nitrate ester		
11	Nitrite		
12	Nitrite ester		
13	Sydnonimine		
14	Sydnone		
15	Oxatriazol-5-imine		
16	Oxatriazol-5-one		
17	Hydroxylamine	$\text{H}_2\text{N}-\text{OH}$	
18	Dioxadiazacyclobutene		
19	N-hydroxynitrosoamine		
20	N-nitrosoimine		
21	N- hydroxycarbamide		

22	Metal nitrosamino complex	$M_aX_b \left[\begin{array}{c} N=O \\ \\ NH_2 \end{array} \right]_n$	
----	---------------------------	---	--

As used herein, the nitric oxide releasing agent may be positively charged, electrically neutral, or negatively charged under physiological conditions. As used herein, the nitric oxide releasing agent may have a logP ranging from 1 to 5. For instance, the nitric oxide releasing agent may have a logP ranging from 1.5 to 3.5.

The nitric oxide releasing agent of the present application may be used to prevent or treat the administration of a VEGFR inhibitor and/or VEGF inhibitor-associated diseases or disorders.

Method Of Preventing and/or Treating Diseases And Related Uses

As used herein, the nitric oxide releasing agent may be used to prepare a medicament for preventing or treating the administration of a VEGFR inhibitor and/or VEGF inhibitor-associated diseases or disorders.

As used herein, the nitric oxide releasing agent may be used to prevent or treat the rash associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, pruritus associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, erythema associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerosis cutis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, alopecia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, paronychia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, pigmentation disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, oral mucositis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerostomia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, epistaxis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nasopharyngitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, cheilitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, esophagitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, esogastritis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, gastric ulcer associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, diarrhea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, vomiting associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nausea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, anorexia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, constipation associated with

administration of the VEGFR inhibitor and/or VEGF inhibitor, and/or, abdominal pain associated with administration of the VEGFR inhibitor and/or VEGF inhibitor. For instance, the nitric oxide releasing agent may be used to prevent or treat hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor.

As used herein, the nitric oxide releasing agent may be used to prevent or treat rash, hand-foot syndrome, pruritus, erythema, xerosis cutis, alopecia, paronychia, pigmentation disorder, oral mucositis, xerostomia, epistaxis, nasopharyngitis, cheilitis, esophagitis, esogastritis, gastric ulcer, diarrhea, vomiting, nausea, anorexia, constipation, and/or, abdominal pain. For instance, the nitric oxide may be used to prevent or treat hand-food syndrome.

In some embodiments, the medicament is formulated to be suitable for topical administration. In some embodiments, the location of topical administration may not be the occurrence site of cancer or potential metastatic site of cancer. For instance, the administering site may be not an occurrence location of tumor. For another instance, the administering site may be not a metastatic site of tumor. For instance, the metastatic site may comprise a site of tumor metastasis caused by lymphatic metastasis, vascular metastasis and/or transcoelomic metastasis. In some embodiments, the metastatic site may comprise bone, brain, liver, stomach and/or lungs. For another instance, the administering site may be not a recurrence site of tumor. In the medicament of the present application, the nitric oxide releasing agent may be present at a concentration of about 0.0001% (w/w) to about 50% (w/w), e.g., it may vary in a range from about 0.0001% (w/w) to about 10% (w/w), from about 0.0001% (w/w) to about 9.5% (w/w), from about 0.0001% (w/w) to about 9% (w/w), from about 0.0001% (w/w) to about 8.5% (w/w), from about 0.0001% (w/w) to about 8% (w/w), from about 0.0001% (w/w) to about 7.5% (w/w), from about 0.0001% (w/w) to about 7% (w/w), from about 0.0001% (w/w) to about 6.5% (w/w), from about 0.0001% (w/w) to about 6% (w/w), from about 0.0001% (w/w) to about 5.5% (w/w), from about 0.0001% (w/w) to about 5% (w/w), from about 0.0001% (w/w) to about 4.5% (w/w), from about 0.0001% (w/w) to about 4% (w/w), from about 0.0001% (w/w) to about 3.5% (w/w), from about 0.0001% (w/w) to about 3% (w/w), from about 0.0001% (w/w) to about 2.5% (w/w), from about 0.0001% (w/w) to about 2% (w/w), from about 0.0001% (w/w) to about 1.5% (w/w), from about 0.0001% (w/w) to about 1% (w/w), from about 0.0001% (w/w) to about 0.5% (w/w), from about 0.0001% (w/w) to about 0.01% (w/w) or less. In the medicament of the present application, the nitric oxide releasing agent may be present as a concentration vary in a range from about 0.0001% (w/w) to about 1% (w/w), about 0.0001% (w/w) to about 0.9% (w/w), from about 0.0001% (w/w) to about 0.6% (w/w), from about 0.05% (w/w) to about 0.5% (w/w), from about 0.05% (w/w) to about 0.4% (w/w), from about 0.05% (w/w) to about 0.3% (w/w), from about 0.05%

(w/w) to about 0.2% (w/w), from about 0.1% (w/w) to about 0.2% (w/w) or less. For instance, the nitric oxide releasing agent may be present at a concentration of about 0.2% (w/w). Or, the nitric oxide releasing agent may be present at a concentration of about 0.1% (w/w).

As used herein, the medicament comprising the nitric oxide releasing agent may not substantially affect the therapeutic effect of the VEGFR inhibitor and/or the VEGF inhibitor. For instance, by administration of a medicament comprising the nitric oxide releasing agent, it is not required to increase the dose of the VEGFR inhibitor and/or the VEGF inhibitor to achieve substantially the same therapeutic effect.

In some embodiments, the medicament is formulated to be suitable for external administration.

In some embodiments, the medicament is formulated to be suitable for topically dermal administration. For instance, the medicament may be ointment, lotion or cream.

As used herein, the medicament may further comprise one or more additional active ingredients. For instance, the active ingredients may refer to a monomeric compound having medical effect or biological activity. For instance, the other active ingredients may be selected from the group consisting of anti-inflammatory agents, analgesics, local anesthetics, antihistamines, preservatives, immunosuppresses, and anti-bleeding agents.

As used herein, the medicament may further comprise a pharmaceutically acceptable carrier. For instance, the pharmaceutically acceptable carrier may be selected from the group consisting of fillers, adhesives, disintegrating agents, buffers, preservatives, lubricants, flavoring agents, thickeners, colorants and emulsifying agents.

In another aspect, the present application provides a nitric oxide releasing agent used to prevent or treat a VEGFR and/or VEGF inhibition-associated disease or disorder (for instance, a VEGFR and/or VEGF inhibition-associated epithelial tissue disease or disorder.)

In another aspect, the present application provides a method of preventing or treating VEGFR and/or VEGF inhibition-associated diseases or disorders in a subject. The method comprising administering to the subject a prophylactically or therapeutically effective amount of the nitric oxide releasing agent of the present application.

As used herein, the term “prevent” may be interchangeably used with “prophylactically treat”. In the present application, the term “prevent” generally refers to prevent the occurrence, reoccurrence or diffusion of diseases or one or more symptoms thereof by taking some actions in advance. As used herein, the term “treat” generally refers to eliminate or improve disease or ameliorate one or more symptoms associated with the diseases.

As used herein, the term “subject” generally refers to a human or non-human animal (including mammals, rodents, and birds, etc.) in need of accepting a diagnosis, prognosis, improvement, prevention, and/or treatment. For instance, the subject may be a livestock (such as cow, pig, goat, chicken, rabbit or horse), or rodents (such as rat and mouse), or primates (such as gorilla and monkey), domestic animals (such as dog and cat). As used herein, the subject may be those subject that need a nitric oxide releasing agent to treat or prevent. As used herein, the subject may comprise cancer patient. For instance, the subject may have been, is and/or will be administrated the VEGFR inhibitor and/or the VEGF inhibitor. For instance, the VEGFR inhibitor and or VEGF inhibitor may be the VEGFR inhibitor and or VEGF inhibitor described in the present application.

As used herein, the severity of the disease or disorder may increase after administrating the VEGFR inhibitor or VEGF inhibitor. For instance, the severity of the disease or disorder may increase about 5% or above, 10% or above, 15% or above, 20% or above, 25% or above, 30% or above, 35% or above, 40% or above, 45% or above, 50% or above, 60% or above, 70% or above, 80% or above, 90% or above, 100% or above, 200% or above or more.

As used herein, the subject may not suffer the disease or disorder before administrating the VEGFR inhibitor and/or VEGF inhibitor. As used herein, the term “the subject doesn’t suffer the disease or disorder” generally refers to the subject has no previous medical history related to the administration of a VEGFR inhibitor and/or VEGF inhibitor-associated disease or disorder. For instance, the subject doesn’t suffer the disease or disorder associated with the administration of the VEGFR inhibitor and/or VEGF inhibitor for one day more, one week more, one month more, one year more, ten years more before administrating the VEGFR inhibitor and/or VEGF inhibitor, or since the subject was born.

As used herein, the VEGFR inhibitor and/or VEGF inhibitor doesn’t comprise the nitric oxide releasing agent. For instance, the VEGFR inhibitor and/or VEGF inhibitor doesn’t comprise nitroglycerin.

As used herein, the term “effective amount” refers to an amount of medicament capable of ameliorating or eliminating diseases or symptoms of the subject, or prophylactically inhibiting or prohibiting the occurrence of diseases or symptoms. In general, the particular effective amount may determine depending on the body weight, age, sex, diet, excretion rate, medical history, current therapy, time of administration, dosage form, administration mode, administration route, combination of medicaments, health conditions or cross infection potential of the subject, allergy, hypersensitivity, and side effects, and/or degree of epithelial (or endothelial) tissue disease development. The skilled man in the art (e.g., physicians or veterinarians) may decrease or increase the administration dosage in portion in accordance with these or other conditions.

In some embodiments, the nitric oxide releasing agent administrated may be present at a concentration of

about 0.0001% (w/w) to about 50% (w/w), e.g., it may vary in a range from about 0.0001% (w/w) to about 10% (w/w), from about 0.0001% (w/w) to about 9.5% (w/w), from about 0.0001% (w/w) to about 9% (w/w), from about 0.0001% (w/w) to about 8.5% (w/w), from about 0.0001% (w/w) to about 8% (w/w), from about 0.0001% (w/w) to about 7.5% (w/w), from about 0.0001% (w/w) to about 7% (w/w), from about 0.0001% (w/w) to about 6.5% (w/w), from about 0.0001% (w/w) to about 6% (w/w), from about 0.0001% (w/w) to about 5.5% (w/w), from about 0.0001% (w/w) to about 5% (w/w), from about 0.0001% (w/w) to about 4.5% (w/w), from about 0.0001% (w/w) to about 4% (w/w), from about 0.0001% (w/w) to about 3.5% (w/w), from about 0.0001% (w/w) to about 3% (w/w), from about 0.0001% (w/w) to about 2.5% (w/w), from about 0.0001% (w/w) to about 2% (w/w), from about 0.0001% (w/w) to about 1.5% (w/w), from about 0.0001% (w/w) to about 1% (w/w), from about 0.0001% (w/w) to about 0.5% (w/w), from about 0.0001% (w/w) to about 0.01% (w/w) or less. In the medicament of the present application, the nitric oxide releasing agent may be present as a concentration vary in a range from about 0.0001% (w/w) to about 1% (w/w), about 0.0001% (w/w) to about 0.9% (w/w), from about 0.0001% (w/w) to about 0.6% (w/w), from about 0.05% (w/w) to about 0.5% (w/w), from about 0.05% (w/w) to about 0.4% (w/w), from about 0.05% (w/w) to about 0.3% (w/w), from about 0.05% (w/w) to about 0.2% (w/w), from about 0.1% (w/w) to about 0.2% (w/w) or less. For instance, the nitric oxide releasing agent may be present at a concentration of about 0.2% (w/w). Or, the nitric oxide releasing agent may be present at a concentration of about 0.1% (w/w).

As used herein, the subject may comprise a human or non-human animal. For instance, the non-human animal may be selected from the group consisting of monkey, chicken, goose, cat, dog, mouse, and rat. Moreover, the non-human animal may further comprise any animal species other than human, e.g., livestock, or rodents, or primates, or domestic animals, or domestic fowls. The human may be Caucasian, African, Asian, Semite, or other races, or a combination of various races. As another example, the human may be elderly, adult, adolescent, child, or infant.

The effective amount in humans may be derived from the effective amount in the laboratory animals. For instance, Freireich et al. describe the relation between the dosages in animals and humans (milligrams per square meter of body surface) (Freireich et al., *Cancer Chemother. Rep.* 50, 219 (1966)). The body surface area may be approximately determined in accordance with the height and body weight of the patient. See, e.g., *Scientific Tables*, Geigy Pharmaceuticals, Ardsley, N.Y., 537 (1970).

In the method of the present application, the VEGFR and/or VEGF inhibition may be caused by administration of the VEGFR inhibitor and/or the VEGF inhibitor to the subject.

For instance, the nitric oxide releasing agent may be administered before, simultaneously with, or after

the administration of the VEGFR inhibitor and/or the VEGF inhibitor to the subject. When the VEGFR inhibitor and/or the VEGF inhibitor and the nitric oxide releasing agent of the present application are simultaneously administered, the nitric oxide releasing agent is administered at a level of about 0.0001-10% (e.g., about 0.005-10%, about 0.01-10%, about 0.05-10%, about 0.1-10%, about 0.2-10%, about 0.3-10%, about 0.4-10%, about 0.5-10%, about 0.6-10%, about 0.7-10%, about 0.8-10%, about 0.9-10%, about 0.95-10%, about 1-10%, about 2-10%, about 3-10%, about 5-10%, about 6-10%, about 8-10% or less) in relative to the total dose. In an embodiment in which the nitric oxide releasing agent and the VEGFR inhibitor and/or the VEGF inhibitor are administered at intervals, the nitric oxide releasing agent may be administered at intervals before or after the administration of the VEGFR inhibitor and/or the VEGF inhibitor. The time interval may be 1 min, 2 mins, 5 mins, 10 mins, 20 mins, 30 mins, 45 mins, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 18 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months or longer.

In some embodiments, the nitric oxide releasing agent is externally administered. In some embodiments, the nitric oxide releasing agent is administered in an ointment. In some embodiments, the nitric oxide releasing agent is administered together with one or more additional active ingredients. In some embodiments, the administration of the nitric oxide releasing agent does not substantially affect the therapeutic effect of the VEGFR inhibitor and/or the VEGF inhibitor.

In another aspect, the present application provides a combination of medicaments (e.g., a kit). The combination of medicaments may comprise: 1) the VEGFR inhibitor and/or the VEGF inhibitor of the present application; and 2) the nitric oxide releasing agent of the present application. In some embodiments, the VEGFR inhibitor and/or the VEGF inhibitor and the nitric oxide releasing agent are not mixed with each other.

In some embodiments, the VEGFR inhibitor and/or the VEGF inhibitor and the nitric oxide releasing agent each independently presents in a separate container. For instance, the combination of medicaments may comprise two or more medicaments which are packaged separately from each other, wherein at least one of the medicaments comprises the VEGFR inhibitor and/or the VEGF inhibitor of the present application and wherein at least one additional medicament comprises the nitric oxide releasing agent of the present application.

In some embodiments of the combination of medicaments, the nitric oxide releasing agent of 2) is capable of preventing or treating the disease or disorder associated with the VEGFR inhibitor and/or the VEGF inhibitor of 1) (e.g., the disease or disorder associated with administration of VEGFR inhibitor or VEGF inhibitor of the present application). In some embodiments, the nitric oxide releasing agent of 2) does not

substantially affect the therapeutic effect of the VEGFR inhibitor and/or the VEGF inhibitor of 1). In some embodiments, the nitric oxide releasing agent of 2) is administered before, simultaneously with, or after the administration of the VEGFR inhibitor and/or the VEGF inhibitor of 1).

As used herein, the term “does not substantially affect” may refer to, comparing to the therapeutic effect of using the VEGFR inhibitor and/or VEGF inhibitor independently, the therapeutic effect of using the nitric oxide releasing agent of 2) or kit and the VEGFR inhibitor and/or VEGF inhibitor of 1) of combination of medicaments is equal, or not worse significantly. For instance, to any subject, compared with therapeutic effect of administration of the VEGFR inhibitor and/ or VEGF inhibitor independently, the decreased tumor volume of administration the nitric releasing agent of 1) and the VEGFR inhibitor and/or VEGF inhibitor of 2) of the combination of medicaments or kit is equal or, decreased by no less than about 5%, no less than about 4%, no less than about 3%, no less than about 2%, no less than about 1%, no less than about 0.5%, no less than about 0.1%, no less than about 0.01%, no less than about 0.001%, or less.

The present application further provides a method comprising administering a nitric oxide releasing agent to a subject, of those the subject has been, is being and/or will be administered a VEGFR inhibitor and/or VEGF inhibitor, and suffer or susceptible to suffer the disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor.

The present application further provides a method comprising administering nitric oxide releasing agent to a subject suffering or susceptible to suffer the disease or disorder, of those the subject has been, is being and/or will be administered a VEGFR inhibitor and/or VEGF inhibitor.

As used herein, the subject may have suffered the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, or, the subject may have greater probability to suffer the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor.

As used herein, the term “susceptible to” generally refer to a subject have a greater probability to suffer a disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. For instance, the greater probability may refer to the probability of a subject suffering the disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor increases by about at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200% or higher, compared with that of a health subject.

The present application further provides a method of preventing or treating diseases or disorders, comprising administering a nitric oxide releasing agent to a subject that suffers or susceptible to the disease or disorder, of those the disease or disorder is hand-food syndrome.

For instance, the subject may have been, is or will be administrated with a VEGFR inhibitor and/or VEGF inhibitor.

For instance, the disease or disorder may be hand-foot syndrome. For instance, the disease or disorder may be a disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor.

For instance, the disease or disorder may be a hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor.

The present application provides a method comprising the steps of: 1) monitoring one or more features of skin tissue, facial organ and/or gastrointestinal tract of a subject administrated a VEGFR inhibitor and/or VEGF inhibitor; 2) when the monitoring shows the subject suffer skin tissue disease or disorder, facial organ disease or disorder and/or gastrointestinal disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, administrating the nitric oxide releasing agent to the subject.

As used herein, the term “features of skin tissue” generally refers to features capable of representing skin tissue disease or disorder. For instance, the features may comprise features capable of representing a disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor. For instance, the feature may comprise feature capable of representing rash associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, hand-foot syndrome associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, pruritus associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, erythema and/or purpura associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, xerosis cutis and/or chapped associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, alopecia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, paronychia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, and/or pigmentation disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor. For instance, the feature may comprise area and degree of erythema, the area and degree of purpura, the numbers and degree of pimples, the numbers and degree of pustule, the numbers and degree of nodule, the range and degree of skin swelling, the degree of skin ulcer, degree of xerosis, degree of skin chapped, degree of skin keratinization, degree of skin lichen, the area and degree of skin desquamation, state of skin tight, degree of skin pruritus, degree of vascular inflammation between dermis with hypodermic, the degree of necrotic skin tissue, the degree of skin ulcer, the area of livedo reticularis, the degree of skin pigmentation, the numbers of blister and bullae, part/area/degree of alopecia, degree of skin granulation, degree of skin seborrhea, degree of folliculitis, the degree of periungual swelling and redness, the degree of paronychia, the pigmentation of periungual skin, the degree of onychatrophia, onychatrophia or onychauxis, abnormal color of nail bed, nail stripe, nail ridge, nail pterygium

and of like.

As used herein, the term “features of facial organ” generally refers to the features representing facial disease or disorder. For instance, the features may comprise the features representing the disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. For instance, the features may comprise the features representing. The feature may comprise feature capable of representing a disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. For instance, the feature may comprise feature capable of representing an oral mucositis associated with administration of a VEGFR inhibitor and/or VEGF inhibitor, xerostomia associated with administration of a VEGFR inhibitor and/or VEGF inhibitor, epistaxis associated with administration of a VEGFR inhibitor and/or VEGF inhibitor, nasopharyngitis associated with administration of a VEGFR inhibitor and/or VEGF inhibitor, and/or cheilitis associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. For instance, the feature may comprise congestion degree of oral mucosa, edema degree of oral mucosa, herpes degree of oral mucosa, ulcer degree of oral mucosa, degree of oral submucosa glandular defect, degree of lingual gland/ sublingual gland /parotid gland and atrophy, the degree of xerostomia, the degree of caries, the degree of tongue swelling, the degree of peripheral tooth mark, frequency of nosebleed, the amount of nosebleed, degree of oropharynx and nasopharynx mucosal edema, degree of oropharynx and nasopharynx mucosal herpes, degree of oropharynx and nasopharynx mucosal ulcer, degree of oropharynx and nasopharynx mucosal hyperplasia, degree of oropharynx and nasopharynx follicular hyperplasia, the degree of lip and around-lip swelling, the degree of lip and around-lip herpes, degree of lip and around-lip erythema, degree of lip and around-lip skin desquamation, degree of lip and around-lip skin lichenification and the degree of lip and around-lip skin erosion and of like.

As used herein, the term “features of gastrointestinal tract” generally refers to feature capable of representing gastrointestinal disease or disorder. For instance, the feature may comprise feature capable of representing a disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. For instance, the feature may comprise capable of representing an esophagitis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, esogastritis associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, gastric ulcer associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, diarrhea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, vomiting associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, nausea associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, anorexia associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, constipation associated with administration of the VEGFR inhibitor and/or VEGF inhibitor, and/or abdominal pain associated with administration of the VEGFR inhibitor

and/or VEGF inhibitor. For instance, the feature may comprise degree of appetite loss, degree of stomach belching, degree of swallowing hard, degree of burning sensation of the sternum, degree of sternal pain, time and degree of upper abdominal pain (when hungry or satiety), degree of bloating, degree of diarrhea, numbers of defecation, defecation time, abdominal pain before defecation, rectal tenesmus, abnormal defecation (such as black-blood stool, fresh-blood stool, mucus stool, mucus-blood stool, watery stool, egg-dropping stool, etc.), vomiting frequency, vomitus situation, nausea, degree of malnutrition, degree of micronutrient deficiency, etc.

As used herein, the method comprises continually monitoring the skin tissue disease or disorder, facial organ disease or disorder and/or gastrointestinal disease or disorder, and optionally reducing or withdrawing the VEGFR inhibitor and/or VEGF inhibitor. For instance, the continually monitoring may refer to monitoring for about at least one day, at least one week, at least ten days, at least two weeks, at least three weeks, at least one month, at least three months, or longer after administration of the VEGFR inhibitor and/or VEGF inhibitor. For instance, the reducing or withdrawing may refer to reducing the dosage of the VEGFR inhibitor and/or VEGF inhibitor administered to the subject by about at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100%, comparing with the dosage of the VEGFR inhibitor and/or VEGF inhibitor administered in step 1) of the method,.

As used herein, the severity of the disease or disorder associated with administration of the VEGFR inhibitor and/or VEGF inhibitor may increase after the administration of VEGFR inhibitor and/or VEGF inhibitor. For instance, the severity may increase by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more.

As used herein, the subject may not suffer the disease or disorder before administrating the VEGFR inhibitor and/or VEGF inhibitor.

As used herein, the VEGFR inhibitor and/or VEGF inhibitor may not comprise the nitric oxide releasing agent. For instance, the VEGFR inhibitor and/or VEGF inhibitor may not comprise nitroglycerin.

As used herein, the disease or disorder may be epithelial tissue disease or disorder.

As used herein, the administration of the VEGFR inhibitor and/or VEGF inhibitor may be used to treat cancer. For instance, the location of the disease or disorder may be different from that of tumor.

As used herein, the nitric oxide releasing agent may be administrated to the subject. For instance, the nitric oxide releasing agent may be administrated topically to the location substantially not comprising tumor cells. As used herein, it may administrate the nitric oxide releasing agent to the subject topically. For instance,

it may administrate the nitric oxide releasing agent to the subject at a site that substantially doesn't comprise tumor cells.

As used herein, the item "the location substantially not comprising tumor cells" generally refer to a tissue organ or location where the amount of cancer cell is low enough to be reckoned as substantially not comprised. For instance, the substantially not comprise may refer to the amount of cancer cells is less than 0.01%, less than 0.005%, less than 0.001%, less than 0.0001%, less than 0.00001% or less of the amount of overall cells of this location.

For another instance, it may administrate the nitric oxide releasing agent to a no-cancer location.

As used herein, the term of "no-cancer location" generally refer to a site that is not a cancer nidus or cancer metastatic site. For instance, the cancer nodus may be an occurrence site of cancer. For instance, the cancer metastatic site may be a place of the same tumor as the tumor of the occurrence site. For instance, the cancer metastatic site may be formed by a lymphatic metastasis, vascular metastasis or transcoelomic metastasis.

In the context of the present invention (especially in the context of the following claims, unless otherwise stated herein or clearly contradictory to the context, the terms "a" and "an" and "the" and "at least a/an/one" and similar referents are to be understood as comprising both singular and plural forms. Unless otherwise stated herein or clearly contradictory to the context, when the term "at least one" is followed by one or more of items as listed (for example, "at least one of A and B"), it is to be understood as one of the listed items (A or B) or any combination of two or more of the listed items (A and B).

Unless otherwise noted, the terms "comprise," "have," "include," and "contain," are intended to mean an open term (i.e., meaning "including, but not limited to").

It is not intended to be bound by any theory, the examples as set forth below are merely for the purpose of illustrating the working modes of the apparatus, method and system of the present application, but not to limit the scope of the invention.

EXAMPLES

In the results of the examples of the present application, ** represents $P < 0.01$; * represents $P < 0.05$; *** represents $P < 0.001$, as statistically detected by using t-test.

Example 1: Synthesis of S-nitrosothiol silica nanospheres

A mixed solution of 4 ml of (3-mercaptopropyl) trimethoxysilane and 2 ml of tetraethyl orthosilicate was injected via an injection pump to a mixed solution of 30 ml of deionized water, 30 ml of ethanol and 30 ml of

ammonia water at a rate of 0.5 ml/min. During injection, the reaction mixture was kept at 0°C. After completion of injection, the reaction mixture was stirred at room temperature for 2.5 hrs., and then centrifuged at 4000 rpm for 8 min. The precipitates were washed once with 100 ml of ice water and 100 ml of ethanol respectively, and dried under vacuum to give thiolated silica nanospheres.

150 mg thiolated silica nanosphere was dispersed in 4 ml of methanol, and cooled to 0 °C. A mixed solution of 2 ml of 1 M sodium nitrite and 1 mM diethyltriaminepentaacetic acid was added under constant stirring, and then 2 ml of 5 M aqueous solution of hydrochloric acid was added. The reaction mixture was stirred in the dark at 0°C for 2.5 hrs., centrifuged at 4 °C at 4000 rpm for 5 mins. The precipitates were washed once with 30 ml of 1mM aqueous solution of diethyltriaminepentaacetic acid at 4 °C and 30 ml of methanol at 4 °C respectively, and centrifuged again for collecting the solid. In the dark and at a temperature below -30 °C, the solid was dried over under vacuum for 30 mins to give the dried final product, which was stored at -20 °C for next use.

The final product was dissolved in a PBS buffer solution of pH = 7.4, and it was measured by using ZS90 Type Particle Size and Zeta Potential Analyzer that the hydrodynamic radius of the product was 423 nm and the polydispersity index was 0.061. The UV-visible spectrum of the solution (as measured by using Thermo Fisher EV300 Type UV spectrophotometer) has a characteristic absorption peak at 330 nm. Under the conditions of 200 W light for 5 hrs., the NO storage was characterized by the total amount of the released nitric oxide as detected by Beyotime NO assay kit (Griess Method, purchased from Shanghai Beyotime Biotechnology Inc.). The NO storage of the final product was measured to be 1.87 ± 0.55 $\mu\text{mol/mg}$.

Example 2: Synthesis of S-nitrosoethanedithiol chitin

2 g of chitin and 5 g of lithium chloride were dispersed in 50 ml of dimethylacetamide, and 20 ml of N,N-diisopropylethylamine was added at 0 °C. 20 g of *p*-toluenesulfonyl chloride was dissolved in 20 ml of dimethylacetamide, and the resultant mixture was added into the chitin-containing solution as prepared above. The mixed solution was stirred at 4 °C for 20 hrs., and then poured into 300 ml of acetone for precipitation and filtration. The precipitates were washed once with 300 ml of methanol, 150 ml of DI water and 300 ml of acetone respectively, and then dried over under vacuum to give *p*-tosylated chitin.

1 g of *p*-tosylated chitin and 2.5 g of lithium chloride were dispersed into 40 ml of dimethylacetamide, and then 3 ml of N,N-diisopropylethylamine and 1.5 ml of 1,2-ethanedithiol were added. The mixed solution was stirred at 60 °C under nitrogen for 24 hrs, and then poured into 400 ml of acetone for precipitation and filtration. The precipitates were washed with 400 ml of methanol and 400 ml of acetone respectively, dried over under vacuum, and then dispersed into a 25 ml solution of 10 mM 1,4-dithiothreitol and

N,N-diisopropylethylamine in dimethylacetamide. The reaction mixture was stirred at room temperature for 1 hr, and filtered. The precipitates were washed once with 400 ml of methanol and 400 ml of acetone respectively, and dried over under vacuum to give thiolated chitin compound. 200 mg thiolated chitin compound was dispersed into a 5 ml mixed solution of dimethylacetamide/methanol (at a volume ratio of 3/1), and 1 ml of tert-butyl nitrite was added and stirred at room temperature for 12 hrs. Then, the mixed solution was added in to 100 ml of methanol and stirred for 30 mins, filtered, and dried under vacuum to give the final product.

The infrared spectroscopy of the final product (as detected by Nicolet 6700 Type infrared spectrometer) has main absorption peaks (wave numbers): 3600-3200, 3285, 1652, 1537, 1028, 3360-3220, 1250-1300, 1050-1070. The diffuse reflectance UV-visible spectrum thereof (as detected by using Thermo Fisher EV300 Type UV spectrophotometer) shows a characteristic absorption peak at 549 nm. Under the conditions of 200 W light for 5 hrs, the NO storage was characterized by the total amount of the released nitric oxide as detected by Beyotime NO assay kit (Griess Method, purchased from Shanghai Beyotime Biotechnology Inc.). The NO storage of the final product was measured to be $0.37 \pm 0.08 \mu\text{mol/mg}$.

Example 3: Synthesis of Oligopropylenediamine-Grafted Chitosan NONOate

250 μL of 2-methylaziridine was mixed with 300 μL of 1 M aqueous solution of hydrochloride, and the mixture was added dropwise into 10 ml of 20 mg/mL chitosan aqueous solution. The mixed solution was stirred at room temperature for 4 days and at 78 °C for 20 hrs, and then poured into 300 ml of acetone for precipitation and centrifugation. The precipitates were washed twice with methanol, and dried over under vacuum to give secondary amine modified chitosan. ^1H NMR spectroscopy (by using Bruker Avance III Type NMR spectrometer, 400 MHz, CD_3OD) shows peaks at 0.8-1.1, 1.9, 2.3-2.7, 3.3-4.0, and 4.4.

50 mg secondary amine modified chitosan was dissolved in a mixed solution of 1 mL of water and 3 mL of methanol, and the mixed solution was added into Parr swing hydrogenator, together with 100 μL of 6 M solution of sodium methoxide. The hydrogenator was repeatedly purged with high purity nitrogen to remove oxygen, filled with gaseous nitric oxide, and kept at 10 atm at room temperature for 4 days for reaction. After completion of reaction, the reaction vessel was repeatedly purged with high purity nitrogen to remove unreacted nitric oxide. Then, the reaction mixture was added into 300 mL of acetone for precipitation, centrifuged to collect the precipitates, and dried under vacuum to give the final product, which was stored at -20 °C for next use.

The infrared spectrum of the final product (comprise diazeniumdiolate) (as detected by using Nicolet 6700 Type infrared spectrometer) comprises main absorption peaks (wave numbers) of: 3600-3200, 3285,

1650, 1587, 1284, and 1059. The UV-visible spectrum thereof (as detected by using Thermo Fisher EV300 Type UV spectrophotometer) comprises a characteristic absorption peak at 252 nm. The sample was dissolved in a PBS solution, and detected by Beyotime NO assay kit (Griess Method) for the total NO releasing amount, so as to determine that the NO storage of the sample which was $0.77 \pm 0.11 \mu\text{mol/mL}$.

Examples 4-15: Effect of Nitric Oxide Releasing Agent on Ameliorating Proliferative Toxicity of VEGF/VEGFR Inhibitor to HUVEC cells and Comparison with Sildenafil

It was tried to use Sildenafil to treat the side effect of Palmar Plantar Erythrodysesthesia (PPE) caused by anti-VEGF multi-kinase inhibitor as reported (see, Kellen L. Meadows et al., *Support Care Cancer*. 2015 May 23 (5):1311–1319) However, the therapeutic effect of Sildenafil against PPE caused by anti-VEGF multi-kinase inhibitors is very limited, almost ineffective. In the present application, the effect of the nitric oxide releasing agent is compared with that of Sildenafil.

The cultured HUVEC cells were digested, suspended, counted and seeded into a 96-well plate with 5000-10000 cells per well. The wells were divided to: the blank control group, the VEGF/VEGFR inhibitor group, the VEGF/VEGFR inhibitor + nitric oxide releasing agent group, the VEGF/VEGFR inhibitor solvent group, the nitric oxide releasing agent solvent control group, the VEGF/VEGFR inhibitor + sildenafil group, and sildenafil solvent control group, wherein each well of each group contained a basic medium, and the final liquid volume contained in each well was about 100 μL . The particular grouping situation was as follows:

- 1) the blank control group: no solution was added except normally replacing the medium;
- 2) the VEGF/VEGFR inhibitor group: a VEGF/VEGFR inhibitor solution (the final concentration was shown in Table 1, and the solvent of the VEGF/VEGFR inhibitor solution was DMSO);
- 3) the VEGF/VEGFR inhibitor + nitric oxide releasing agent group: a VEGF/VEGFR inhibitor solution and a nitric oxide releasing agent solution were added (the final concentrations of the VEGF/VEGFR inhibitor and the nitric oxide releasing agent were shown in Table 1, the solvent of the nitric oxide releasing agent solution was selected as ethanol or sterile water depending on the solubility of the nitric oxide releasing agent, and the slight difference of the total volume of each group was complemented by adding the corresponding solvent as selected);
- 4) the VEGF/VEGFR inhibitor solvent group: an equal volume of DMSO as contained in the corresponding VEGF/VEGFR inhibitor solution in Group 2) was added;
- 5) the nitric oxide releasing agent solvent control group: an equal volume of the same type of solvent (e.g., ethanol or sterile water) as contained in the corresponding nitric oxide releasing agent solution in Group 3);

6) the VEGF/VEGFR inhibitor +Sildenafil group: a VEGF/VEGFR inhibitor solution was first added, and then a Sildenafil solution was added (the final concentrations of the VEGF/VEGFR inhibitor and Sildenafil were shown in Table 2, the solvent of the Sildenafil solution was DMSO, and the slight difference of the total volume of each group was complemented by adding the corresponding solvent as selected);

7) the Sildenafil solvent control group: an equal volume of DMSO as contained in the corresponding Sildenafil solution in Group 6) was added.

The VEGF/VEGFR inhibitor solvent group was not subject to data processing, and only served as a reference for evaluating the system error of experiments. The nitric oxide releasing agent solvent control group and the Sildenafil solvent control group were used for data correction, thereby eliminating the effect of solvents on results.

After cultured for additional 24-48 hours, the survival rate of cells was determined by Cell Counting Kit-8 (CCK-8) assay kit (C0037, Shanghai Beyotime Biotechnology Inc., Beyotime Biotechnology), to calculate the amelioration effect of VEGF/VEGFR inhibitor to proliferative toxicity and the ameliorating effect of the nitric oxide releasing agent or Sildenafil to the proliferative toxicity. GraphPad Prism 6.0 Software and t-test were used to carry out a statistic analysis of the results and plot a graph.

Table 2 lists various combinations of the VEGF/VEGFR inhibitor with the nitric oxide releasing agent or Sildenafil, and the corresponding experimental results (wherein, the data as listed in the cell survival rate column were the percentages of viable cells increased by the VEGF/VEGFR inhibitor + nitric oxide releasing agent group (or Sildenafil), as compared to the VEGF/VEGFR inhibitor group). FIG. 4A-4C represent the exemplary results of cell proliferative toxicity as determined by the CCK-8 method after 24 hours from the administration of the VEGF/VEGFR inhibitor sorafenib tosylate (V1) or Sunitinib malate (V3) or Regorafenib (V4) and the nitric oxide releasing agent (or Sildenafil) to the HUVEC cells, respectively. Of those, the horizontal axis represents different experiment groups and control groups, and the vertical axis represents the cell survival rate (the survival percentage of other experimental groups or solvent control groups is calculated based on 100% of the cell survival rate of the blank control group). Of those, *** represents $P<0.001$; ** represents $P<0.01$, indicating that it has significant difference from the corresponding group in which the VEGF/VEGFR inhibitor is administered alone; * represents $P<0.05$, indicating that it has significant difference from the corresponding group in which the VEGF/VEGFR inhibitor is administered alone; as statistically detected by using t-test.

Table 2: Experimental Conditions and Results of Examples 4-15

Table 2. Experimental Conditions and Results of Examples 4-15					
Ex No.	VEGFR inhibitor	Final Concentration	Nitric oxide releasing agent	Final Concentration	Cell Survival Rate
4	Sorafenib	5 μM	Nitroglycerin	100 μM	Increased by 50-60%
	Apatinib	10 μM			Increased by 60-70%
	Sunitinib	5 μM			Increased by 50-60%
	Regorafenib	10μM			Increased by 30-40%
	Lenvatinib Mesylate	10μM			Increased by 30-50%
	Pazopanib	10μM			Increased by 20-30%
	Axitinib	10μM			Increased by 20-30%
	Nintedanib Esylate	10μM			Increased by 30-50%
	Thalidomide	10μM			Increased by 20-30%
5	Sorafenib	5 μM	Molsidomine	100 μM	Increased by 30-40%
	Apatinib	10 μM			Increased by 40-50%
	Sunitinib	5 μM			Increased by 20-30%
	Regorafenib	10 μM			Increased by 20-30%
	Lenvatinib Mesylate				Increased by 30-50%
	Pazopanib Hydrochloride				Increased by 20-30%
	Axitinib				Increased by 20-30%
	Nintedanib Esylate				Increased by 30-50%
Thalidomide	Increased by 20-30%				

6	Sorafenib	5 μM	Nicorandil	100 μM	Increased by 50-60%
	Regorafenib	10 μM			Increased by 20-30%
	Sunitinib	5 μM			Increased by 10-20%
	Lenvatinib Mesylate	10 μM			Increased by 30-50%
	Pazopanib Hydrochloride				Increased by 20-30%
	Axitinib				Increased by 20-30%
	Nintedanib Esylate				Increased by 30-50%
	Thalidomide				Increased by 20-30%
	Apatinib				Increased by 40-50%
7	Sorafenib	5 μM	Isoamyl Nitrite	100 μM	Increased by 30-40%
	Sunitinib	5 μM			Increased by 20-25%
	Regorafenib	10 μM			Increased by 15-20%
	Lenvatinib Mesylate	10 μM			Increased by 30-50%
	Pazopanib Hydrochloride				Increased by 20-30%
	Axitinib				Increased by 20-30%
	Nintedanib Esylate				Increased by 30-50%
	Thalidomide				Increased by 20-30%
	Apatinib				Increased by 40-50%
8	Regorafenib	10 μM	Isosorbide Dinitrate	100 μM	Increased by 15-20%
	Sunitinib	5 μM			Increased by

					20-30%
	Sorafenib	5 μ M			Increased by 20-30%
9	Regorafenib	10 μ M	3-morpholinosydnonimine (SIN-1) linsidomine	100 μ M	Increased by 15-20%
	Sunitinib	5 μ M			Increased by 10-20%
	Sorafenib	5 μ M			Increased by 30-40%
10	Regorafenib	10 μ M	Isosorbide Mononitrate	100 μ M	Increased by 20-30%
	Sunitinib	5 μ M			Increased by 20-25%
	Sorafenib	5 μ M			Increased by 30-35%
11	Regorafenib	10 μ M	Pentaerythritol Tetranitrate	100 μ M	Increased by 20-25%
	Sunitinib	5 μ M			Increased by 25-35%
	Sorafenib	5 μ M			Increased by 30-40%
12	Regorafenib	10 μ M	3,3-Bis (aminoethyl) -1-hydroxy-2-oxo-1-triazene (NOC-18)	100 μ M	Increased by 15-20%
	Sunitinib	5 μ M			Increased by 20-30%
	Sorafenib	5 μ M			Increased by 35-45%
13	Regorafenib	10 μ M	S-nitrosothiol silica nanospheres	0.30 mg/mL	Increased by 10-30%
	Sunitinib	5 μ M			Increased by 15-30%
	Sorafenib	5 μ M			Increased by 20-25%
14	Regorafenib	10 μ M	Oligopropylenediamine-grafted chitosan NONOate	1.80 mg/mL	Increased by 20-25%
	Sunitinib	5 μ M			Increased by 20-30%
	Sorafenib	5 μ M			Increased by 30-50%
15	Regorafenib	10 μ M	Sildenafil	100 μ M	No

	Sunitinib	5 μ M			significant
	Sorafenib	5 μ M			change

It can be seen from the results in Table 2 and FIG. 4A-4C that the nitric oxide releasing agents produce a significantly ameliorating effect on the proliferative toxicity, and the ameliorating effect thereof is substantially better than Sildenafil.

Examples 16-32: Effect of Nitric Oxide Releasing Agent on Ameliorating Proliferative Toxicity of VEGF/VEGFR Inhibitor to Human Immortalized Epithelial Cells (HaCaT), Human Oral Mucosa Epithelial Keratinocytes (HOK), Human Small Intestinal Epithelial Cells (FHs 74 Int), Gastric Epithelial Cells (GES-1) and Comparison with Sildenafil

A variety of epithelial cells were cultured for use in experiments, wherein: Examples 16-20 utilized human immortalized epithelial cells (HaCaT), and the results correspond to Table 3; Examples 21-24 utilized human oral mucosa epithelial keratinocytes (HOK), and the results correspond to Table 4; Examples 25-28 utilized gastric epithelial cells (GES-1), and the results correspond to Table 5; Examples 29-32 utilized human small intestinal epithelial cells (FHs 74 Int), and the results correspond to Table 6.

The cultured cells were digested, suspended, counted, and seeded into a 96-well plate with 5000-10000 cells per well. The wells were divided to: the blank control group, the VEGF/VEGFR inhibitor group, the VEGF/VEGFR inhibitor + nitric oxide releasing agent group, the VEGF/VEGFR inhibitor solvent group, the nitric oxide releasing agent solvent control group, the VEGF/VEGFR inhibitor + Sildenafil group, and Sildenafil solvent control group, wherein each well of each group contained a basic medium, and the final liquid volume contained in each well was about 100 μ L. The particular grouping situation was as follows:

- 1) the blank control group: no solution was added except normally replacing the medium;
- 2) the VEGF/VEGFR inhibitor group: a VEGF/VEGFR inhibitor solution (the final concentration was shown in Table 2, and the solvent of the VEGF/VEGFR inhibitor solution was DMSO);
- 3) the VEGF/VEGFR inhibitor + nitric oxide releasing agent group: a VEGF/VEGFR inhibitor solution and a nitric oxide releasing agent solution were added (the final concentrations of the VEGF/VEGFR inhibitor and the nitric oxide releasing agent were shown in Table 2, the solvent of the nitric oxide releasing agent solution was selected as ethanol or sterile water depending on the solubility of the nitric oxide releasing agent, and the slight difference of the total volume of each group was complemented by adding the corresponding solvent as selected);
- 4) the VEGF/VEGFR inhibitor solvent group: an equal volume of DMSO as contained in the corresponding VEGF/VEGFR inhibitor solution in Group 2) was added;
- 5) the nitric oxide releasing agent solvent control group: an equal volume of the same type of solvent

(e.g., ethanol or sterile water) as contained in the corresponding nitric oxide releasing agent solution in Group 3);

- 6) the VEGF/VEGFR inhibitor + sildenafil group: a VEGF/VEGFR inhibitor solution was first added, and then a Sildenafil solution was added (the final concentrations of the VEGF/VEGFR inhibitor and Sildenafil were shown in Table 2, the solvent of the Sildenafil solution was DMSO, and the slight difference of the total volume of each group was complemented by adding the corresponding solvent as selected);
- 7) the Sildenafil solvent control group: an equal volume of DMSO as contained in the corresponding sildenafil solution in Group 6) was added.

The VEGF/VEGFR inhibitor solvent group was not subject to data processing, and only served as a reference for evaluating the system error of experiments. The nitric oxide releasing agent solvent control group and the sildenafil solvent control group were used for data correction, thereby eliminating the effect of solvents on results.

After cultured for additional 24-48 hours, the survival of cells was determined by Cell Counting Kit-8 (CCK-8) assay kit (C0037, Shanghai Beyotime Biotechnology Inc., Beyotime Biotechnology), to calculate the proliferative toxicity of the VEGF/VEGFR inhibitor to cells and the ameliorating effect of the nitric oxide releasing agent to the proliferative toxicity. GraphPad Prism 6.0 Software and t-test were used to carry out a statistic analysis of the results and plot a graph.

Tables 3-6 list various combinations of the VEGF/VEGFR inhibitor and the nitric oxide releasing agent or Sildenafil, and the corresponding experimental results (wherein, the data as listed in the cell survival rate column were the percentages of viable cells increased by the VEGF/VEGFR inhibitor + nitric oxide releasing agent group (or Sildenafil), as compared to the VEGF/VEGFR inhibitor group). FIG. 5 represents the experimental results on HaCaT cells, FIG. 6 represents the experimental results on HOK cells, FIG. 7 represents the experimental results on GES-1 cells, FIG. 8 represents the experimental results on FHs 74 Int cells. Of those, the horizontal axis represents the experimental results on different experimental groups and control groups; and the vertical axis represents the survival rate of cells (the survival percentage of cells in other experimental groups or solvent control group is calculated based on 100% of the cell survival rate of the blank control group) wherein FIGs 5A, 6A, 7A and 8A each represents the exemplary results of cell proliferative toxicity as determined by the CCK-8 method after 24 hours from the administration of the VEGF/VEGFR inhibitor Sorafenib tosylate (V1) and the nitric oxide releasing agent (or Sildenafil) to different types of cells; FIGs. 5B, 6B, 7B and 8B each represents the exemplary results of cell proliferative toxicity as

determined by the CKK-8 method after 24 hours from the administration of the VEGF/VEGFR inhibitor Sunitinib malate (V3) and the nitric oxide releasing agent (or Sildenafil) to different types of cells; and FIG. 5C, 6C, 7C and 8C each represent the exemplary results of cell proliferative toxicity as determined by the CKK-8 method after 24 hours from the administration of the VEGF/VEGFR inhibitor Regorafenib (V4) and the nitric oxide releasing agent (or Sildenafil) to different types of cells. Of those, *** represents $P < 0.001$, indicating a significant difference as compared with the control group which is administered with the VEGF/VEGFR inhibitor alone; ** represents $P < 0.01$, indicating a significant difference as compared with the control group which is administered with the VEGF/VEGFR inhibitor alone; * represents $P < 0.05$, indicating a significant difference as compared with the control group which is administered with the VEGF/VEGFR inhibitor alone; as statistically detected by using t-test.

Table 3 Experimental Conditions and Results of Examples 16-20

Ex. No.	VEGFR Inhibitor	Final Concentration	Nitric Oxide Releasing Agent	Final Concentration	Cell Survival Rate
16	Sorafenib	10 μ M	Isoamyl Nitrite	100 μ M	Increased by 15-20%
	Regorafenib	10 μ M			Increased by 28-35%
	Sunitinib	10 μ M			Increased by 35-45%
17	Sorafenib	10 μ M	Molsidomine	100 μ M	Increased by 15-20%
	Regorafenib	10 μ M			Increased by 20-25%
	Sunitinib	10 μ M			Increased by 55-65%
18	Sorafenib	10 μ M	Nitroglycerin	100 μ M	Increased by 30-40%
	Regorafenib	10 μ M			Increased by 30-40%
	Sunitinib	10 μ M			Increased by 50-60%
19	Sorafenib	10 μ M	Nicorandil	100 μ M	Increased by 15-20%
	Regorafenib	10 μ M			Increased by 15-20%
	Sunitinib	10 μ M			Increased by

					50-60%
20	Regorafenib	10 μ M	Sildenafil	100 μ M	No significant change
	Sunitinib	10 μ M			
	Sorafenib	10 μ M			

It can be seen from the results in Table 3 and FIG. 5 that the VEGF/VEGFR inhibitors have a proliferative toxicity on skin cells (HaCaT), while the nitric oxide releasing agents have a significantly ameliorating effect on the proliferative toxicity caused by the VEGF/VEGFR inhibitors, and the ameliorating effect is substantially better than Sildenafil.

Table 4 Experimental Conditions and Results of Examples 21-24

Ex. No.	VEGFR inhibitor	Final Concentration	Nitric oxide releasing agent	Final Concentration	Cell Survival Rate
21	Sorafenib	10 μ M	Isoamyl Nitrite	100 μ M	Increased by 90-100%
	Regorafenib	10 μ M			Increased by 65-75%
	Sunitinib	10 μ M			Increased by 15-20%
22	Sorafenib	10 μ M	Molsidomine	100 μ M	Increased by 90-100%
	Regorafenib	10 μ M			Increased by 60-70%
	Sunitinib	10 μ M			Increased by 15-20%
23	Sorafenib	10 μ M	Nitroglycerin	100 μ M	Increased by 90-100%
	Regorafenib	10 μ M			Increased by 80-90%
	Sunitinib	10 μ M			Increased by 20-30%
24	Sorafenib	10 μ M	Nicorandil	100 μ M	Increased by 90-100%
	Regorafenib	10 μ M			Increased by 60-70%
	Sunitinib	10 μ M			Increased by 15-20%
20	Regorafenib	10 μ M	Sildenafil	100 μ M	No significant change
	Sunitinib	10 μ M			
	Sorafenib	10 μ M			

It can be seen from the results in Table 4 and FIG. 6 that the VEGF/VEGFR inhibitors have a proliferative toxicity on human oral mucosa epithelial keratinocytes (HOK), while the nitric oxide releasing

agents have a significantly ameliorating effect on the proliferative toxicity caused by the VEGF/VEGFR inhibitors, and the ameliorating effect is substantially better than Sildenafil.

Table 5 Experimental Conditions and Results of Examples 25-28

Ex. No.	VEGFR inhibitor	Final Concentration	the nitric oxide releasing agent	Final Concentration	Cell Survival Rate
25	Sorafenib	10 μ M	Isoamyl Nitrite	100 μ M	Increased by 15-20%
	Regorafenib	10 μ M			Increased by 20-30%
	Sunitinib	10 μ M			Increased by 40-50%
26	Sorafenib	10 μ M	Molsidomine	100 μ M	Increased by 20-30%
	Regorafenib	10 μ M			Increased by 20-30%
	Sunitinib	10 μ M			Increased by 15-20%
27	Sorafenib	10 μ M	Nitroglycerin	100 μ M	Increased by 30-40%
	Regorafenib	10 μ M			Increased by 40-50%
	Sunitinib	10 μ M			Increased by 70-80%
28	Sorafenib	10 μ M	Nicorandil	100 μ M	Increased by 20-30%
	Regorafenib	10 μ M			Increased by 20-30%
	Sunitinib	10 μ M			Increased by 30-40%
20	Regorafenib	10 μ M	Sildenafil	100 μ M	No significant change
	Sunitinib	10 μ M			
	Sorafenib	10 μ M			

It can be seen from the results in Table 5 and FIG. 7 that the VEGF/VEGFR inhibitors have a proliferative toxicity on gastric epithelial cells (GES-1), while the nitric oxide releasing agents have a significantly ameliorating effect on the proliferative toxicity caused by the VEGF/VEGFR inhibitors, and the ameliorating effect is substantially better than Sildenafil.

Table 6 Experimental Conditions and Results of Examples 29-32

Ex. No.	VEGFR inhibitor	Final Concentration	the nitric oxide releasing agent	Final Concentration	Cell Survival Rate
29	Sorafenib	10 μ M	Isoamyl Nitrite	100 μ M	Increased by 40-50%
	Regorafenib	10 μ M			Increased by 10-15%
	Sunitinib	10 μ M			Increased by 45-55%
30	Sorafenib	10 μ M	Molsidomine	100 μ M	Increased by 40-50%
	Regorafenib	10 μ M			Increased by 10-15%
	Sunitinib	10 μ M			Increased by 10-15%
31	Sorafenib	10 μ M	Nitroglycerin	100 μ M	Increased by 60-70%
	Regorafenib	10 μ M			Increased by 20-30%
	Sunitinib	10 μ M			Increased by 70-80%
32	Sorafenib	10 μ M	Nicorandil	100 μ M	Increased by 40-50%
	Regorafenib	10 μ M			Increased by 10-15%
	Sunitinib	10 μ M			Increased by 45-55%
20	Regorafenib	10 μ M	Sildenafil	100 μ M	No significant change
	Sunitinib	10 μ M			
	Sorafenib	10 μ M			

It can be seen from the results in Table 6 and FIG. 8 that the VEGF/VEGFR inhibitors have a proliferative toxicity on human intestinal epithelial cells (FHs 74 Int), while the nitric oxide releasing agents have a significantly ameliorating effect on the proliferative toxicity caused by the VEGF/VEGFR inhibitors, and the ameliorating effect is substantially better than Sildenafil.

Examples 33-46: Determination of effect of the nitric oxide releasing agent on intra/extra-cellular NO level

The cultured HUVEC, HaCaT, HOK, FHs 74 Int or GES-1 cells were digested, suspended, counted, and

seeded into a 24-well plate with 100,000-200,000 cells per well. After the cells were attached, a nitric oxide releasing agent solution was added to achieve a particular final concentration (e.g., as shown in Tables 7-8). A medium was added into the control group. At various time points after administration of the nitric oxide releasing agent (6 hours, 12 hours, 24 hours and 48 hours, e.g., as shown in Tables 7-8), 50 μ L of supernatant of each group was collected for detecting the NO level in the extracellular supernatant. Meanwhile, the remainder supernatant was discarded, and a cell lysis solution was added. After sufficient lysis, 50 μ L of lysate was taken for detecting the intracellular NO level. A NO Assay kit (S0021, Beyotime Inc.) was used for detecting the NO level.

Of those, FIGs. 9A-9D each represent the relative NO levels in HUVEC extracellular, HUVEC intracellular, GES-1 extracellular and GES-1 intracellular at 6 h, 12 h, 24 h, 48 h from administration of the nitric oxide releasing agent. NTG represents nitroglycerin. The control group was the basic medium, reflecting the biological level.

FIGs. 10A-10D each represent the relative extracellular NO levels in HUVEC cells, GES-1 cells, HaCaT cells, and HOK cells after 24 hours of treatment with the nitric oxide releasing agent (isosorbide dinitrate, nicorandil, molsidomine, and isoamyl nitrite). The control group was the basic medium, reflecting the biological level. Of those, ** represents $P < 0.01$, indicating a significant difference as compared with the corresponding control group; * represents $P < 0.05$, indicating a significant difference as compared with the corresponding control group; as statistically analyzed by using t-test.

FIGs. 11A-11D each represent the relative intracellular NO levels in HUVEC cells, GES-1 cells, HaCaT cells, and HOK cells after 24 hours of treatment with the nitric oxide releasing agent (isosorbide dinitrate, nicorandil, molsidomine, and isoamyl nitrite). The control group was the basic medium, reflecting the biological level. Of those, *** represents $P < 0.001$, indicating a significant difference as compared with the corresponding control group; ** represents $P < 0.01$, indicating a significant difference as compared with the corresponding control group; * represents $P < 0.05$, indicating a significant difference as compared with the corresponding control group; as statistically analyzed by using t-test.

It can be seen from the results in Tables 7-8 and FIGs. 9-11 that the nitric oxide releasing agent can release nitric oxide and increase the intracellular NO level.

Table 7 Experimental Conditions and Results of Examples 33-39

Ex. No.	Medicament	Final Concentration	Cell Type (Extracellular)	Time Point	NO Level
33	Nitroglycerin (NTG)	100 μ M	HUVEC	6h	Increased by 70-80%
				12h	Increased by

					100-120%
				24h	Increased by 200-235%
				48h	Increased by 180-210%
34	Nitroglycerin (NTG)	100µM	GES-1	6h	Increased by 70-85%
				12h	Increased by 87-128%
				24h	Increased by 170-185%
				48h	Increased by 125-155%
35	Isosorbide Dinitrate	100µM	HUVEC	24h	Increased by 135-165%
	Nicorandil	100µM			Increased by 75-90%
	Molsidomine	100µM			Increased by 75-85%
	Isoamyl Nitrite	100µM			Increased by 80-95%
36	Isosorbide Dinitrate	100 µM	HaCaT	24h	Increased by 120-150%
	Nicorandil	100µM			Increased by 85-110%
	Molsidomine	100µM			Increased by 66-85%
	Isoamyl Nitrite	100µM			Increased by 100-120%
37	Isosorbide Dinitrate	100 µM	HOK	24h	Increased by 122-156%
	Nicorandil	100µM			Increased by 80-100%
	Molsidomine	100µM			Increased by 60-80%
	Isoamyl Nitrite	100µM			Increased by 125-147%
38	Isosorbide Dinitrate	100 µM	FHs 74 Int	24h	Increased by 110-150%
	Nicorandil	100µM			Increased by 80-100%
	Molsidomine	100µM			Increased by 50-80%
	Isoamyl Nitrite	100µM			Increased by

					110-125%
39	Isosorbide Dinitrate	100 µM	GES-1	24h	Increased by 135-174%
	Nicorandil	100µM			Increased by 80-110%
	Molsidomine	100µM			Increased by 55-80%
	Isoamyl Nitrite	100µM			Increased by 130-150%

Table 8 Experimental Conditions and Results of Examples 40-46

Ex. No.	Medicament	Final Concentration	Cell Type (Intracellular)	Time Point	NO Level
40	Nitroglycerin (NTG)	100µM	HUVEC	6h	Increased by 10-20%
				12h	Increased by 45-70%
				24h	Increased by 45-60%
				48h	Increased by 1-20%
41	Nitroglycerin (NTG)	100µM	GES-1	6h	Increased by 10-30%
				12h	Increased by 20-35%
				24h	Increased by 20-25%
				48h	Increased by 20-30%
42	Isosorbide Dinitrate	100µM	HUVEC	24h	Increased by 40-55%
	Nicorandil	100µM			Increased by 30-45%
	Molsidomine	100µM			Increased by 15-25%
	Isoamyl Nitrite	100µM			Increased by 15-30%
43	Isosorbide Dinitrate	100 µM	HaCaT	24h	Increased by 20-40%
	Nicorandil	100µM			Increased by 15-30%
	Molsidomine	100µM			Increased by 10-25%
	Isoamyl Nitrite	100µM			Increased by 20-40%
44	Isosorbide Dinitrate	100 µM	HOK	24h	Increased by 20-40%

	Nicorandil	100μM			Increased by 10-30%
	Molsidomine	100μM			Increased by 9-30%
	Isoamyl Nitrite	100μM			Increased by 15-35%
45	Isosorbide Dinitrate	100 μM	FHs 74 Int	24h	Increased by 15-35%
	Nicorandil	100μM			Increased by 10-30%
	Molsidomine	100μM			Increased by 10-25%
	Isoamyl Nitrite	100μM			Increased by 20-35%
46	Isosorbide Dinitrate	100 μM	GES-1	24h	Increased by 20-40%
	Nicorandil	100μM			Increased by 15-25%
	Molsidomine	100μM			Increased by 10-30%
	Isoamyl Nitrite	100μM			Increased by 25-35%

Examples 47-54: Sildenafil neither release nitric oxide, nor increase the intra- and extracellular NO levels of HUVEC, HaCaT or GES-1

The cultured HUVEC, HaCaT or GES-1 cells were digested, suspended, counted, and seeded into 6-well plate with 500,000-1,000,000 cells per well. After the cells were attached, a Sildenafil solution was added to achieve a particular final concentration (e.g., as shown in Tables 9-10). A basic medium was added into the control group. At various time points after addition of Sildenafil (6 hours, 12 hours, 24 hours and 48 hours), 50 μL of supernatant of each group was collected for detecting the extracellular NO level. Meanwhile, the remainder supernatant was discarded, and a cell lysis solution was added. After sufficient lysis, 50 μL of lysate was taken for detecting the intracellular NO level. A NO Assay kit (S0021, Beyotime Inc.) was used for detecting the NO level. FIGs. 12-13 lists the experimental results.

Of those, FIGs. 12A-12B each represent the relative extra- and intra-cellular NO levels at various time points after treatment of HUVEC cells with 100 μM of Sildenafil (6 hours, 12 hours, 24 hours, 48 hours). FIGs. 12C-12D each represent the relative extra- and intra-cellular NO levels at 24 hours after treatment of HUVEC cells with different concentrations of Sildenafil. The control group was the basic medium, reflecting the biological level.

FIGs. 13A-13B each represent the relative extra- and intra-cellular NO levels at 24 hours from treatment

of GES-1 cells with 100 μ M of Sildenafil. FIGs. 13C-13D each represent the relative extra- and intra-cellular NO levels at 24 hours from treatment of HaCaT cells with 100 μ M of Sildenafil. The control group was the basic medium, reflecting the biological level.

It can be seen from these results that Sildenafil neither release nitric oxide, nor increase the intra- and extracellular NO levels of HUVEC, HaCaT or GES-1 cells.

Table 9 Experimental Conditions and Results of Examples 47-50

Ex. No.	Medicament	Final Concentration	Cell Type (Extracellular)	Time Point	NO Level
47	Sildenafil	20 μ M	HUVEC	24h	No significant change
		100 μ M			
		200 μ M			
		500 μ M			
48	Sildenafil	100 μ M	HUVEC	6h	
				12h	
				24h	
				48h	
49	Sildenafil	100 μ M	HaCaT	24h	
50	Sildenafil	100 μ M	GES-1	24h	

Table 10 Experimental Conditions and Results of Examples 51-54

Ex. No.	Medicament	Final Concentration	Cell Type (Intracellular)	Time Point	NO Level
51	Sildenafil	20 μ M	HUVEC	24h	No significant change
		100 μ M			
		200 μ M			
		500 μ M			
52	Sildenafil	100 μ M	HUVEC	6h	
				12h	
				24h	
				48h	
53	Sildenafil	100 μ M	HaCaT	24h	
54	Sildenafil	100 μ M	GES-1	24h	

Examples 55-108: The nitric oxide releasing agent is capable of *in vivo* preventing/treating hand-foot syndrome caused by small molecular VEGFR/VEGF inhibitors

Construction of rat animal model: A small molecular VEGFR/VEGF inhibitor as shown in Table 11 was administered to an 8-week SD female rat by daily gavage, and after several days the symptoms of hand-foot syndrome appeared on paws of the rat (e.g., as shown in FIG. 14). Similar to humans, the rat develops the symptoms of hand-foot syndrome after administration of the VEGFR/VEGF inhibitors, and the symptoms were highly similar in human and rat. Thus, rats are very good animal models for mimicking the side effects (e.g., hand-foot syndrome) caused by the VEGFR/VEGF inhibitors.

The rats (about 200 g) were fed for one week, and then divided to groups (each of which comprised 10

rats) for gavage administration experiments. A variety of small molecular VEGFR/VEGF inhibitors were dissolved in a mixed solution having a ratio of Cremophor EL: ethanol=1:1. Prior to gavage, the VEGFR/VEGF inhibitors medicament solution was diluted with PBS to the desired concentration (about 3 times diluted with a PBS solution). The gavage amount was not more than 2 mL, and the dosage was shown in Table 11. After gavage, the left paw of rat (palm and gaps of the paw) was topically administered with an ointment containing a nitric oxide releasing agent (about 0.05g), while the right paw was not administered as the blank control. After administration, the rat was fixed in a fixed cylinder for 4 hours. After 4 hours, the rat was released, wiped with water to remove the residual medicament on the administered site, and returned to the cage. The gavage frequency of the VEGFR/VEGF inhibitor is shown in Table 11, but the nitric oxide releasing agent was administered only once per day. The gavage and administration were repeated every day, until the experiment ended. The number of rats on which the administered side kept normal or the symptoms of hand-foot -syndrome was substantially less serious than the side not administrated after 15-18 days of administration was counted as the number of rats in which the hand-foot syndrome was effectively inhibited.

Table 11 lists various combinations of animal models of the VEGFR/VEGF inhibitors and the nitric oxide releasing agent ointments, and the corresponding experimental results (wherein, the value in the control rate column = the number of rats in which the hand-foot syndrome was effectively inhibited in each group/the number of the hand-foot syndrome models in each group $\times$ 100%; the success rate of the hand-foot syndrome model in each group is 30% to 70%, that is, there are about 3-7 successful hand-foot syndrome models among 10 rats; during the modelling process, death of individual rat or unsuccessful modelling occur in different administration groups, death of individual rat or unsuccessful modelling in different drug groups).

Table 11 Experimental Conditions and Results of Examples 55-108

Experiment No.	VEGFR/VEGF inhibitor	Dosage	Frequency	Administration	Concentration	Administered Paw	Days	Control Rate
55	Sorafenib	80mg/kg	once daily	Nitroglycerin ointment	0.05%	Left	15	66.67%
56	Sorafenib	80mg/kg	once daily	Nitroglycerin ointment	0.15%	Left	15	71.43%
57	Sorafenib	80mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	15	60%
58	Apatinib	105mg/kg	once daily	Nitroglycerin ointment	0.05%	Left	15	60%
59	Apatinib	105mg/kg	once daily	Nitroglycerin ointment	0.15%	Left	15	60%
60	Apatinib	105mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	15	75%
61	Lenvatinib	65mg/kg	twice daily	Nitroglycerin ointment	0.05%	Left	18	50%
62	Lenvatinib	65mg/kg	twice daily	Nitroglycerin ointment	0.15%	Left	18	40%

63	Lenvatinib	65mg/kg	twice daily	Nitroglycerin ointment	0.2%	Left	18	60%
64	Regorafenib	90mg/kg	once daily	Nitroglycerin ointment	0.05%	Left	18	50%
65	Regorafenib	90mg/kg	once daily	Nitroglycerin ointment	0.15%	Left	18	60%
66	Regorafenib	90mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	18	57.14%
67	Sunitinib	120mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	15	50%
68	Cabozantinib	50mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	18	66.67%
69	Axitinib	50mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	18	50%
70	Nintedanib	110mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	18	75%
71	Brivanib	80mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	18	33.33%
72	Vatalanib succinate	150mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	15	50%
73	Fruquintinib	40mg/kg	once daily	Nitroglycerin ointment	0.2%	Left	16	66.67%
74	Sorafenib	80mg/kg	once daily	Isosorbide Mononitrate/Isosorbide Dinitrate (1: 1) mixed ointment	0.2%	Left	15	42.86%
75	Apatinib	105mg/kg	once daily	Isosorbide Mononitrate/Isosorbide Dinitrate (1: 1) mixed ointment	0.2%	Left	15	50%
76	Lenvatinib	65mg/kg	twice daily	Isosorbide Mononitrate/Isosorbide Dinitrate (1: 1) mixed ointment	0.2%	Left	18	50%
77	Regorafenib	90mg/kg	once daily	Isosorbide Mononitrate/Isosorbide Dinitrate (1: 1) mixed ointment	0.2%	Left	18	42.86%
78	Sunitinib	120mg/kg	once daily	Isosorbide Mononitrate/Isosorbide Dinitrate (1: 1) mixed ointment	0.2%	Left	15	33.33%
79	Sorafenib	80mg/kg	once daily	Nicorandil ointment	0.2%	Left	15	33.33%
80	Lenvatinib	65mg/kg	twice daily	Nicorandil ointment	0.2%	Left	18	42.86%
81	Regorafenib	90mg/kg	once daily	Nicorandil ointment	0.2%	Left	18	40%
82	Apatinib	105mg/kg	once daily	Nicorandil ointment	0.2%	Left	15	25%
83	Sorafenib	80mg/kg	once daily	Sodium nitrate ointment	0.2%	Left	15	33.33%
84	Lenvatinib	65mg/kg	twice daily	Sodium nitrate ointment	0.2%	Left	18	42.86%
85	Regorafenib	90mg/kg	once daily	Sodium nitrate ointment	0.2%	Left	18	50%
86	Apatinib	105mg/kg	once daily	Sodium nitrate ointment	0.2%	Left	15	40%
87	Sorafenib	80mg/kg	once	Isoamyl Nitrite	0.2%	Left	15	33.33%

		g	daily	ointment				%
88	Lenvatinib	65mg/k g	twice daily	Isoamyl Nitrite ointment	0.2%	Left	18	42.86 %
89	Regorafenib	90mg/k g	once daily	Isoamyl Nitrite ointment	0.2%	Left	18	40%
90	Apatinib	105mg/ kg	once daily	Isoamyl Nitrite ointment	0.2%	Left	15	20%
91	Sorafenib	80mg/k g	once daily	Sodium nitrite ointment	0.2%	Left	15	42.86 %
92	Lenvatinib	65mg/k g	twice daily	Sodium nitrite ointment	0.2%	Left	18	33.33 %
93	Sorafenib	80mg/k g	once daily	Molsidomine ointment	0.2%	Left	15	33.33 %
94	Lenvatinib	65mg/k g	twice daily	Molsidomine ointment	0.2%	Left	18	40%
95	Sorafenib	80mg/k g	once daily	sodium nitroprusside ointment	0.2%	Left	15	42.86 %
96	Lenvatinib	65mg/k g	twice daily	sodium nitroprusside ointment	0.2%	Left	18	28.57 %
97	Sorafenib	80mg/k g	once daily	S-nitrosothiol silica nanospheres ointment	0.2%	Left	15	40%
98	Lenvatinib	65mg/k g	twice daily	S-nitrosothiol silica nanospheres ointment	0.2%	Left	18	33.33 %
99	Sorafenib	80mg/k g	once daily	S-nitrosoethanedithiol chitin ointment	0.2%	Left	15	28.57 %
100	Lenvatinib	65mg/k g	twice daily	S-nitrosoethanedithiol chitin ointment	0.2%	Left	18	16.67 %
101	Sorafenib	80mg/k g	once daily	oligopropylenediamine -grafted chitosan NONOate ointment	0.2%	Right	15	20%
102	Lenvatinib	65mg/k g	twice daily	oligopropylenediamine -grafted chitosan NONOate ointment	0.2%	Right	18	14.29 %
103	Sorafenib	80mg/k g	once daily	N-nitrosodibutylamine ointment	0.2%	Right	15	33.33 %
104	Lenvatinib	65mg/k g	twice daily	N-nitrosodibutylamine ointment	0.2%	Right	18	25%
105	Sorafenib	80mg/k g	once daily	hydroxyldiazenesulfoni c acid-1-oxide disodium salt ointment	0.2%	Right	15	20%
106	Lenvatinib	65mg/k g	twice daily	hydroxyldiazenesulfoni c acid-1-oxide disodium salt ointment	0.2%	Right	18	33.33 %
107	Sorafenib	80mg/k g	once daily	streptozocin ointment	0.2%	Right	15	20%
108	Lenvatinib	65mg/k g	twice daily	streptozocin ointment	0.2%	Right	18	16.67 %

NOTE: The modelling success rate of anti-cancer medicaments are not constant: the success rate of the hand-foot syndrome model in each group is 30% to 70%, that is, there are about 3-7 successful hand-foot syndrome models among 10 rats, during the modelling process, death of individual rat or unsuccessful modelling occur in different administration groups. The control rate refers to the ratio of the number of rats in which the symptoms on the administered paw are less serious than the paw not administrated to the total number of the hand-foot syndrome model rats in the experimental groups.

It can be seen from the results in Table 11 that the nitric oxide releasing agent is capable of effectively preventing and treating the hand-foot syndrome caused by the VEGFR/VEGF inhibitors. Meanwhile, the results of FIGs. 15-16 also show that the nitric oxide releasing agent is capable of effectively preventing and treating the hand-foot syndrome caused by the VEGFR/VEGF inhibitors. FIG. 15 shows that in the administration groups of Examples 55-100, a typical rat was administered on its left paw (with a nitric oxide releasing agent ointment), and the hand-foot syndrome on its left paw were significantly ameliorated; FIG. 16 shows that in the administration groups of Examples 101-108, a typical rat was administered on its right paw (with a nitric oxide releasing agent ointment), and the hand-foot syndrome on its right paw are also significantly ameliorated.

Examples 109-110: The nitric oxide releasing agent is capable of *in vivo* preventing/treating the hand-foot syndrome caused by a small molecular VEGFR/VEGF inhibitor

Preparation of *Nitrosomonas europaea* lotion: Inoculated *Nitrosomonas europaea* (ATCC 19718) into inorganic medium (ATCC 2265), cultured at about 200rpm, 26°C, dark condition for 3-5days until the medium turned turbid to obtain bacterial stock liquid. Diluted the stock liquid to different concentration of solution with the inorganic medium (such as 10^7 、 10^8 、 10^9 、 10^{10} cell/ml). The concentration of bacterial was determined with a cytometer, and then, obtain the *Nitrosomonas europaea* lotion.

Construction of rat animal model: A small molecular VEGFR/VEGF inhibitor as shown in Table 12 was administered to an 8-week SD female rat by daily gavage, and after several days the symptoms of hand-foot syndrome appeared on paws of the rat. Similar to humans, the rat develops the symptoms of hand-foot syndrome after administration of the VEGFR/VEGF inhibitors, and the symptoms were highly similar in human and rat. Thus, rats are very good animal models for mimicking the side effects (e.g., hand-foot syndrome) caused by the VEGFR/VEGF inhibitors.

The rats (about 200 g) were fed for one week, and then divided to groups (each of which comprised 10 rats) for gavage administration experiments. A variety of small molecular VEGFR/VEGF inhibitors were dissolved in a mixed solution having a ratio of Cremophor EL: ethanol=1:1. Prior to gavage, the VEGFR/VEGF inhibitors medicament solution was diluted with PBS to the desired concentration (about 3 times diluted with a PBS solution). The gavage amount was not more than 2 mL, and the dosage was shown in Table 12. After gavage, the rat was fixed in a fixed cylinder. The left paw of rat was soaked with bacterial lotion. After 10 min, the rat was released, once a day, while the right paw was not soaked as the blank control. The gavage frequency of the VEGFR/VEGF inhibitor is shown in Table 12, but the nitric oxide releasing agent was administered only once per day. The gavage and soaking experiment were repeated every day, until the rat

died. The number of rats on which the soaking side kept normal or the symptoms of hand-foot -syndrome was substantially less serious than the unadministered side after 15-18 days of administration was counted as the number of rats in which the hand-foot syndrome was effectively inhibited.

Table 12 lists various combinations of animal models of the VEGFR/VEGF inhibitors and the nitric oxide releasing agent ointments, and the corresponding experimental results (wherein, the value in the control rate column = the number of rats in which the hand-foot syndrome was effectively inhibited in each group/the number of the hand-foot syndrome models in each group $\times 100\%$; the success rate of the hand-foot syndrome model in each group is 30% to 70%, that is, there are about 3-7 successful hand-foot syndrome models among 10 rats; during the modelling process, death of individual rat or unsuccessful modelling occur in different administration groups, death of individual rats occurs in each administration group).

Table 12 Experimental Conditions and Results of Examples 109-110

Experiment No.	VEGFR inhibitor	Dosage	Frequency	Administration	Concentration wt%	Administered Paw	Days	Control Rate
109	Sorafenib	80mg/kg	once daily	Bacterial lotion	10^9 bacteria/mL	左	15	33.33 %
110	Lenvatinib	65mg/kg	twice daily	Bacterial lotion	10^9 bacteria/mL	左	15	25%

It can be seen from Table 12 that the nitric oxide releasing agent is capable of effectively preventing and treating the hand-foot syndrome caused by the VEGFR/VEGF inhibitors.

Examples 111-112: The nitric oxide releasing agent is capable of *in vivo* preventing/treating the hand-foot syndrome caused by a protein macromolecular VEGFR/VEGF inhibitor

Ramucirumab or Bevacizumab was diluted with normal saline to the desired concentration. Rats (about 200 g) were fed for one week, and then divided to groups (each of which comprised 10 rats) for injection administration experiments. The diluted Ramucirumab was administered by intravenous infusion for 60 mins with a dosage of 40 mg/kg. It was administered once per week, together with administration of paclitaxel (10mg/kg). The left paw (the palm and gaps of paw) of the rat was topically administered with an ointment containing a nitric oxide releasing agent (about 0.05g), while the right paw was not administered as the blank control. After administration, the rat was fixed in a fixed cylinder for 4 h. After 4 h, the rat was released, wiped with water to remove the residual medicament on the administered site, and returned to the cage. The experiments lasted for 2-4 weeks. The experimental phenomena were observed, until the experimental rat died and the experiment was over.

Table 13 lists various combinations of animal models of the VEGFR/VEGF inhibitors and the nitric oxide

releasing agent ointments, and the corresponding experimental results (wherein, the value in the control rate column = the number of rats in which the hand-foot syndrome was effectively inhibited in each group/the number of the hand-foot syndrome models in each group $\times 100\%$; the success rate of hand-foot syndrome modelling in each group is 10% to 30%, that is, there are about 1-3 hand-foot syndrome models in 10 rats)

Table 13 Experimental Conditions and Results of Examples 111-112

Experi ment No.	VEGFR inhibitor/VE GF inhibitor	Classi fication of Inhibi tor	Dosage	Frequenc y	Admin istration	Con centr ation	Ad min ister ed Paw	Da ys	Control Rate
111	Ramucirumab	Mono clonal antibo dy	Administered in combination with paclitaxel, injected over 60min	Intraperit oneally injected once per week	Nitrogl lycerin ointme nt	0.2%	Left	23	50%
112	Bevacizumab	Mono clonal antibo dy	Administered in combination with 5-FU, injected over 60-90 mins	Injected through caudal vein once per week	Nitrogl lycerin ointme nt	0.2%	Left	18	50%

NOTE: The modelling success rate of anti-cancer medicaments are not constant: The success rate of hand-foot syndrome in each group is 10%-30%, that is, there are about 1-3 hand-foot syndrome models in 10 rats, during the modelling process, death of individual rat or unsuccessful modelling in different administration groups. The control rate refers to the ratio of the number of rats in which the symptoms on the administered paw are less serious than the unadministered paw to the total number of the hand-foot syndrome model rats in the experimental groups.

FIG. 15 shows the conditions of the left paw, front side, and right paw of a typical rat in the administration groups of examples 111-112, after it was topically administered on its left paw (with a nitric oxide releasing agent ointment).

It can be seen from the results in Table 13 and FIG. 15 that the nitric oxide releasing agent ointment is capable of effectively preventing the hand-foot syndrome caused by the monoclonal antibody-based

VEGFR/VEGF inhibitors.

Examples 113-124: Experiments for demonstrating the ability of treating the hand-foot syndrome caused by the small molecular VEGFR/VEGF inhibitors in rat models

Rats (about 200 g) were fed for one week, and then divided to groups (each of which comprised 10 rats) for gavage administration experiments. A VEGFR/VEGF inhibitor was dissolved in a mixed solution having a ratio of Cremophor EL: ethanol = 1:1, and diluted with PBS to the desired concentration (about 3 times diluted with a PBS solution) prior to gavage. The gavage amount was not more than 2 mL, and the dosage was shown in Table 14. The gavage was repeated every day for VEGFR/VEGF inhibitor, until the rat developed the symptoms of hand-foot syndrome. At this time, the therapeutic experiment was initiated. During the process of therapeutic experiments, the rat was continuously subject to gavage with the VEGFR/VEGF inhibitor at a low frequency (the frequency of gavage was described as Table 14). After gavage, the rat was topically administered on its left paw (palm and gaps of paw) with a nitric oxide releasing agent ointment (about 0.05g), while the right paw was not administered as the blank control. After administration, the rat was fixed in a fixed cylinder for 4 hours. After 4 hours, the rat was released, wiped with water to remove the residual medicament on the administered site, and returned to the cage. The gavage frequency of the VEGFR/VEGF inhibitor is shown in Table 14, but the nitric oxide releasing agent was administered only once per day. After 6-10 days of administration, the number of rats in which the administered side returned to normal or exhibited significantly less serious than the side not administrated was counted as the number of rats in which the hand-foot syndrome was effectively inhibited.

Table 14 summarizes animal studies of administration of various small molecular VEGFR/VEGF inhibitors and the nitric oxide releasing agent ointments, and the corresponding experimental results (wherein, the value in the ameliorated ratio = the number of rats in which the hand-foot syndrome was effectively treated in each group/the number of the hand-foot syndrome models in each group x 100%).

Table 14 Experimental Conditions and Results of Examples 113-124

Experiment No.	VEGFR inhibitor	Dosage	Frequency	Days of Administration Modelling	Administration	Days of Administration	Concentration	administration Paw	Ameliorated Rate
113	Sorafenib	80 mg/kg	Once per day during modelling, and once per two days after the treatment was initiated	8	Nitroglycerin ointment	5	0.2%	Left	50%
114	Apatinib	105 mg/kg	Once per day during modelling, and once per two days after the treatment was initiated	10	Nitroglycerin ointment	5	0.2%	Left	40%
115	Lenvatinib	65mg/kg	Twice per day during modelling, and once per day after the treatment was initiated	13	Nitroglycerin ointment	6	0.2%	Left	42.86%

116	Regoraf enib	90mg/ kg	Once per day during modell ing, and once per two days after the treatm ent was initiate d	12	Nitroglyc erin ointment	5	0.2%	Left	33.33%
117	Sunitini b	120m g/kg	Once per day during modell ing, and once per two days after the treatm ent was initiate d	10	Nitroglyc erin ointment	6	0.2%	Left	40%
118	Sorafeni b	80 mg/kg	Once per day during modell ing, and once per two days after the treatm ent was initiate d	8	Isosorbid e Dinitrate and Isosorbid e Mononitr ate mixed ointment	8	0.2%	Left	50%
119	Apatini b	105 mg/kg	Once per day during modell ing,	10	Isosorbid e Dinitrate and Isosorbid e	7	0.2%	Left	50%

			and once per two days after the treatm ent was initiate d		Mononitr ate mixed ointment				
120	Sorafeni b	80 mg/kg	Once per day during modell ing, and once per two days after the treatm ent was initiate d	8	Nicorandi l ointment	9	0.2%	Left	40%
121	Apatini b	105 mg/kg	Once per day during modell ing, and once per two days after the treatm ent was initiate d	10	Nicorandi l ointment	9	0.2%	Left	40%
122	Sorafeni b	80 mg/kg	Once per day during modell ing, and once per two days after	8	sodium nitropruss ide ointment	8	0.2%	Left	20%

			the treatm ent was initiate d						
123	Sorafen ib	80 mg/kg	Once per day during modell ing, and once per two days after the treatm ent was initiate d	8	a polymer ointment	10	0.2%	Left	33.33%
124	Sorafen ib	80 mg/kg	Once per day during modell ing, and once per two days after the treatm ent was initiate d	8	Molsido mine ointment	8	0.2%	Right	16.67%

NOTE: The modelling success rate of anti-cancer medicaments are not constant: The success rate of hand-foot syndrome in each group is 40%-70%, that is, there are about 1-3 hand-foot syndrome models in 10 rats, during the modelling process, death of individual rat or unsuccessful occur in different administration groups. The control rate refers to the ratio of the number of rats in which the symptoms on the administered paw are less serious than the unadministered paw to the total number of the hand-foot syndrome model rats in the experimental groups.

FIG. 17 shows the conditions of the left paw, front side, and right paw of a typical rat in the administration groups of examples 113-124 after it was topically administered on its left paw (with a nitric oxide releasing agent ointment). FIG. 18 shows the conditions of the left and right paws of a typical rat in the

administration group of examples 124 after it was administrated on its right paw (with a nitric oxide releasing agent ointment).

It can be seen from the results in Table 14 and FIG. 17-18 that the nitric oxide releasing agent ointment is capable of effectively treating the hand-foot syndrome caused by the small molecular VEGFR inhibitors.

Examples 125-142: Comparison of 0.2% nitroglycerin ointment with other currently clinically available investigational medicaments and other nitric oxide releasing agents in the experiments of preventing the hand-foot syndrome caused by the small molecular VEGFR/VEGF inhibitors

Rats (about 200 g) were fed for one week, divided to groups (each of which comprised 10 rats), and then subjected to gavage administration experiments. A VEGFR inhibitor was dissolved in a mixed solution having a ratio of Cremophor EL: ethanol=1:1, and diluted with PBS to the desired concentration (about 3 times diluted with a PBS solution) prior to gavage. The gavage amount was not more than 2 mL, and the dosage was shown in Table 15. After gavage, the left paw (palm and gaps of paw) of the rat was topically administered with nitroglycerin ointment (about 0.05g), and the right paw was topically administered with the currently clinically available investigational medicaments or the other nitric oxide releasing agent ointment in in the same manner. After administration, the rat was fixed by a fixed cylinder for about 4 hours. After 4 hours, the rat was released, wiped with water to remove the residual medicament on the administered site, and returned to the cage. The gavage frequency of the VEGFR/VEGF inhibitors is shown in Table 15, but the clinically available other skin medicaments and the nitric oxide releasing agents were administered only once. The rat was subject to gavage with the VEGFR/VEGF inhibitors, until the paw administered with the clinically available investigational medicament (or the other nitric oxide releasing agent) developed the symptoms of hand-foot syndrome or the rat died. After 15-18 days of administration, the number of rats in which the paw administered with nitroglycerin ointment exhibited normal or significantly less serious than the paw administered with the clinically investigational medicament (or the other nitric oxide releasing agent) was counted as the number of rats in which the hand-foot syndrome was effectively prevented.

Table 15 lists the combination of experiments of 0.2% nitroglycerin ointments and clinically investigational medicaments (or the other nitric oxide releasing agent), and the corresponding experimental results (wherein, the value in the relative ameliorated rate column = the number of rats in which the hand-foot syndrome on the left paw was significantly less serious than the hand-foot syndrome on the right paw in each group/the hand-foot syndrome model in each group $\times 100\%$).

Table 15 Experimental Conditions and Results of Examples 125-142

Experiment No.	VEGFR inhibitor	Dosage	Frequency	Administration		Administration Days	Relative Ameliorated Rate
				Left	Right		
125	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	1% Sildenafil	15	66.67%
126	Apatinib	105mg/kg	once per day	0.2% Nitroglycerin ointment	1% Sildenafil	15	75%
127	Lenvatinib	100mg/kg	twice per day	0.2% Nitroglycerin ointment	1% Sildenafil	18	60%
128	Regorafenib	90mg/kg	once per day	0.2% Nitroglycerin ointment	1% Sildenafil	18	75%
129	Sunitinib	120mg/kg	once per day	0.2% Nitroglycerin ointment	1% Sildenafil	15	66.67%
130	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	urea frost	15	60%
131	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	Vaseline ointment	15	66.67%
132	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	Urea ointment	15	57.14%
133	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	brimonidine ointment	15	60%
134	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	vitamin B6 ointment	15	57.14%
135	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	Nicotine ointment	15	66.67%
136	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	Dexamethasone ointment	15	75%
137	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	hydrocortisone ointment	15	60%
138	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	Vk1 ointment (0.1%)	15	66.67%
139	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	erythrocine ointment	15	66.67%
140	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	triamcinolone ointment	15	60%
141	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	0.2% Isoamyl Nitrite ointment	15	50%
142	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	0.2% streptozocin ointment	15	60%

It can be seen from the results in Table 15 that as compared with 1% Sildenafil, 0.2% nitroglycerin ointments are capable of effectively controlling the hand-foot syndrome caused by the VEGFR inhibitor and/or the VEGF inhibitor; as compared with the currently clinically available other investigational medicaments (which produce almost no therapeutically effect on the hand-foot syndrome caused by the VEGFR inhibitor and/or the VEGF inhibitor), 0.2% nitroglycerin ointments are capable of effectively inhibiting the hand-foot

syndrome caused by the VEGFR inhibitor and/or the VEGF inhibitor; as compared with other the nitric oxide releasing agent ointments, 0.2% nitroglycerin ointments are capable of more effectively controlling the hand-foot syndrome caused by the VEGFR inhibitor and/or the VEGF inhibitor. The concentration of 0.2% nitroglycerin ointments is significantly lower than the concentrations of the currently clinically available other investigational medicaments, which can be seen 0.2% nitroglycerin ointments has an unexpected technological effect.

Examples 143: Effect of the nitric oxide releasing agent on the therapeutic effect of the VEGFR/VEGF inhibitor

BALB/C nude mouse (liver cancer cell HepG2 transplanted tumor) model was constructed. After the models were stable, the model mice were divided to three groups (in which the average of the rat tumor size kept uniform as possible), each of which comprised 10 mice, which were subject to gavage and topical administration experiments.

A VEGFR inhibitor was dissolved in a mixed solution having a ratio of Cremophor EL: ethanol=1:1 (volumetric ratio), and diluted with PBS to the desired concentration (about 3 times diluted with a PBS solution) prior to gavage. The gavage amount was not more than 0.2 mL, and the dosage was 30mg/kg per day. The tumor-bearing mouse was orally administered Sorafenib every day for the purpose of controlling or reducing the tumor. Meanwhile, a medicament for treating the side effect was externally administered on the back of the mouse in a manner of external administration (the particular grouping was as follows: Group A: gavage + administration with excipient; Group B: gavage + administration with 0.15% nitroglycerin ointment; Group C: gavage + administration with 0.2% nitroglycerin ointment; about 5.8 cm² of administered area were labelled with a marking pen, and the administered area cannot be an area which the mouth of mouse can touch or an area closely near the tumor). After completion of gavage every day, a blank ointment was topically administered to uniform to the labelled area of the back of the model mouse to keep the skin moist. After administration, each mouse was held in a relatively independent space for 4 hours. After 4 hours, the residual ointment on the back of mouse was wiped off with a paper towel or a wetter paper towel. Then, the mouse was returned to the former cage for normal activity. The tumor size was measured and recorded every two days. After 20 days of experiments, the mouse was dissected. The tumor was removed, weighed and recorded. The change of tumor volume of different experimental groups was observed.

The experimental results are shown in FIG. 19. It can be seen from the results in FIG. 19 that in different experimental groups, the tumor volume of the groups administered with ointment (Group B or Group C) is less than the experiment group (Group A), and the tumor volume of Group C is close to or slightly less than the

tumor volume of Group B. Thus, it can be seen that the external ointment containing the nitric oxide releasing agent would not reduce the effects of the VEGFR/VEGF inhibitor on tumors.

Examples 144-145: Effect of Nitric Oxide Releasing Agent on Ameliorating Proliferative Toxicity of VEGF/VEGFR Inhibitor to HUVEC, HaCaT cells and Comparison with Calcium Channel Blockers

It has been reported that calcium channel blockers (such as, Diltiazem) may be used to treat the side effect of Hand-Foot Syndrome (HFS) caused by anti-VEGFR multi-kinase inhibitor (see, U.S. Patent Application US2016/0101114A1). However, the therapeutic effect of Diltiazem against HFS caused by anti-VEGFR multi-kinase inhibitors is very limited. In the present application, the effect of the nitric oxide releasing agent is compared with that of calcium channel blockers.

The cultured HUVEC, HaCat cells were digested, suspended, counted and seeded into a 96-well plate with 5000 cells per well. The wells were divided to: the blank control group, the VEGF/VEGFR inhibitor group, the VEGF/VEGFR inhibitor + nitric oxide releasing agent group, the VEGF/VEGFR inhibitor solvent group, the nitric oxide releasing agent solvent control group, the VEGF/VEGFR inhibitor + calcium channel blocker group, and calcium channel blocker solvent control group, wherein each well of each group contained a basic medium, and the final liquid volume contained in each well was about 100 μ L. The particular grouping situation was as follows:

- 1) the blank control group: no solution was added except normally replacing the medium;
- 2) the VEGF/VEGFR inhibitor group: a VEGF/VEGFR inhibitor solution (the final concentration was shown in Table 16, and the solvent of the VEGF/VEGFR inhibitor solution was DMSO);
- 3) the VEGF/VEGFR inhibitor + nitric oxide releasing agent group: a VEGF/VEGFR inhibitor solution and a nitric oxide releasing agent solution were added (the final concentrations of the VEGF/VEGFR inhibitor and the nitric oxide releasing agent were shown in Table 16, the solvent of the nitric oxide releasing agent solution was selected as ethanol or sterile water depending on the solubility of the nitric oxide releasing agent, and the slight difference of the total volume of each group was complemented by adding the corresponding solvent as selected);
- 4) the VEGF/VEGFR inhibitor solvent group: an equal volume of DMSO as contained in the corresponding VEGF/VEGFR inhibitor solution in Group 2) was added;
- 5) the nitric oxide releasing agent solvent control group: an equal volume of the same type of solvent (e.g., ethanol or sterile water) as contained in the corresponding nitric oxide releasing agent solution in Group 3);
- 6) the VEGF/VEGFR inhibitor + calcium channel blocker group: a VEGF/VEGFR inhibitor solution

was first added, and then a calcium channel blocker solution was added (the final concentrations of the VEGF/VEGFR inhibitor and Sildenafil were shown in Table 16, the solvent of the Sildenafil solution was DMSO, and the slight difference of the total volume of each group was complemented by adding the corresponding solvent as selected);

- 7) the calcium channel blocker solvent control group: an equal volume of DMSO as contained in the corresponding calcium channel blocker solution in Group 6) was added.

The VEGF/VEGFR inhibitor solvent group was not subject to data processing, and only served as a reference for evaluating the system error of experiments. The nitric oxide releasing agent solvent control group and the calcium channel blocker solvent control group were used for data correction, thereby eliminating the effect of solvents on results.

After cultured for additional 24 hours, the survival rate of cells was determined by Cell Counting Kit-8 (CCK-8) assay kit (C0037, Shanghai Beyotime Biotechnology Inc., Beyotime Biotechnology), to calculate to calculate the amelioration effect of VEGF/VEGFR inhibitor to proliferative toxicity and the ameliorating effect of the nitric oxide releasing agent or calcium channel blocker to the proliferative toxicity. GraphPad Prism 6.0 Software and t-test were used to carry out a statistic analysis of the results and plot a graph.

Table 16 lists various combinations of the VEGF/VEGFR inhibitor with the nitric oxide releasing agent or (calcium channel blocker) and the corresponding experimental results (wherein, the data as listed in the cell survival rate column were the percentages of viable cells increased by the VEGF/VEGFR inhibitor + nitric oxide releasing agent group (or calcium channel blocker), as compared to the VEGF/VEGFR inhibitor group).

FIG. 20 represents the exemplary results of cell proliferative toxicity as determined by the CCK-8 method after 24 hours from the administration of the VEGF/VEGFR inhibitor sorafenib tosylate (V1) and the nitric oxide releasing agent (or Diltiazem) to the HUVEC cells, respectively. FIG. 21 represents the exemplary results of cell proliferative toxicity as determined by the CCK-8 method after 24 hours from the administration of the VEGF/VEGFR inhibitor sorafenib tosylate (V1) and the nitric oxide releasing agent (or calcium channel blocker) to the HaCat cells, respectively. Of those, the horizontal axis represents different experiment groups and control groups, and the vertical axis represents the cell survival rate (the survival percentage of other experimental groups or solvent control groups is calculated based on 100% of the cell survival rate of the blank control group). Of those, *** represents $P < 0.001$; ** represents $P < 0.01$; * represents $P < 0.05$, indicating that it has significant difference from the corresponding group in which the VEGF/VEGFR inhibitor is administered alone; as statistically detected by using t-test.

Table 16 Experimental Conditions and Results of Examples 144-145

Ex No.	Cell Type	VEGFR inhibitor	Final Concentration	Nitric oxide releasing agent	Final Concentration	Cell Survival Rate
144	HUVEC	Sorafenib (V1)	10 μ M	Nitroglycerin	50 μ M	Increased by 25-50%
				Isosorbide Mononitrate	50 μ M	Increased by 20-40%
				Diltiazem	50 μ M	Decreased significantly
145	HaCaT	Sorafenib (V1)	10 μ M	Nitroglycerin	50 μ M	Increased by 20-40%
				Isosorbide Dinitrate	50 μ M	Increased by 20-50%
				Isosorbide Mononitrate	50 μ M	Increased by 20-50%
				Diltiazem	50 μ M	No significant increase or decrease
				Verapamil	50 μ M	
				Nifedipine	50 μ M	

Examples 146: Determination of effect of the nitric oxidereleasing agent (or Calcium Channel Blocker) on extra-cellular NO level

Compared effect of the nitric oxide releasing agent with calcium channel blocker on the concentration of extra-cellular NO. The results showed calcium channel blocker was not capable of increasing the concentration of extra-cellular NO, and was not capable of producing NO, therefore calcium channel blocker is not a nitric oxide releasing agent.

The cultured HaCaT cells were digested, suspended, counted, and seeded into a 24-well plate with 200,000 cells per well. After the cells were attached, a nitric oxide releasing agent (or calcium channel blocker) solution was added to achieve a particular final concentration (e.g., as shown in Tables 17). A basic medium was added into the control group. At 24 hours after administration of the nitric oxide releasing agent (or calcium channel blocker), 50 μ L of supernatant of each group was collected for detecting the NO level in the extracellular supernatant. A NO Assay kit (S0021, Beyotime Inc.) was used for detecting the NO level.

FIGs. 22 represents the relative extracellular NO levels in outside HaCaT cells after 24 hours of treatment with the nitric oxide releasing agent (or calcium channel blocker). The control group was the basic medium, reflecting the biological level. Of those, *** represents $P < 0.001$, ** represents $P < 0.01$, * represents $P < 0.05$, indicating a significant difference as compared with the corresponding control group; as statistically analyzed by using t-test.

Table 17 Experimental Conditions and Results of Examples 146

Ex. No.	Medicament	Final Concentration	Cell Type (Extracellular)	Time Point	NO Level
146	Nitroglycerin	100 μ M	HaCaT	24h	Increased by 800-1000%
	Isosorbide Dinitrate	100 μ M			Increased by 100-300%
	Nifedipine	100 μ M			No Significant Change
	Diltiazem	100 μ M			
	Verapamil	100 μ M			

Example 147: Determination of the effect of the nitric oxide releasing agent on expression levels of Calmodulin and Calreticulin in HaCat cell

Calmodulin (CaM) is an intermediate calcium-binding messenger protein and an intracellular target of the secondary messenger Ca^{2+} (Chin D and Means AR, 2000). Calmodulin acts as part of a calcium signal transduction pathway and the binding of Ca^{2+} is required for the activation of calmodulin, therefore calmodulins usually act as marker of calcium signal transduction pathway (Berchtold and Villalobo, 2014). The binding between calreticulin (CRT) with Ca^{2+} inactivates it (Michalak M, et al., 2002). In the present application, compared effect of the nitric oxide releasing agent with calcium channel blocker on expression levels of calmodulin and calreticulin in HaCat cell

The cultured HaCaT cells were digested, suspended, counted, and seeded into a 6-well plate with 200,000 cells per well. After the cells were attached, a nitric oxide releasing agent (or calcium channel blocker) solution was added to achieve a particular final concentration. A basic medium was added into the control group. At 24 hours after administration of the nitric oxide releasing agent (or calcium channel blocker), RIPA lysate (P0013C, Beyotime Biotechnology) was used to extract protein. The change of expressions of calmodulin and calreticulin was determined by Western Blot.

FIG. 23 represents the expression level of calmodulin (CaM) in HaCaT cells after 24 hours of treatment with the nitric oxide releasing agent (or calcium channel blocker). FIG 24 represents the result of gray value analysis of relative expression of calmodulin. FIG 25 represents the expression level of calreticulin (CRT) in HaCaT cells after 24 hours of treatment with the nitric oxide releasing agent (or calcium channel blocker). FIG 26 represents the result of gray value analysis of relative expression of calreticulin.

Image Lab was used to analyze the gray value results. GraphPad Prism 6.0 Software and t-test were used to carry out a statistic analysis of the results and plot a graph. Of those, *** represents $P < 0.001$, ** represents $P < 0.01$, * represents $P < 0.05$, indicating a significant difference as compared with the corresponding control group; as statistically analyzed by using t-test.

It can be seen from the results in FIGs 23-24 that compared with the control group, the calmodulin of the nitric oxide releasing agent group had no significant change, while the calmodulin of calcium channel blocker diltiazem group decreased significantly. The results in FIGs 25-26 show that compared with the control group, the calreticulin of the nitric oxide releasing agent group reduced slightly, while the expression of calreticulin of calcium channel blocker nifedipine group increased significantly. Therefore, the nitric oxide releasing agent doesn't belong to calcium channel blocker.

Examples 148-159: Comparison of 0.2% nitroglycerin ointment and other nitric oxide releasing agents with calcium channel blocker in the experiments of preventing the hand-foot syndrome caused by the small molecular VEGFR/VEGF inhibitors

Rats (about 200 g) were fed for one week, divided to groups (each of which comprised 10 rats), and then subjected to gavage administration experiments. A VEGFR/VEGF inhibitor was dissolved in a mixed solution having a ratio of Cremophor EL: ethanol=1:1, and diluted with PBS to the desired concentration (about 3 times diluted with a PBS solution) prior to gavage. The gavage amount was not more than 2 mL, and the dosage was shown in Table 18. After gavage, the left paw (palm and gaps of paw) of the rat was topically administered with nitroglycerin ointment (or other nitric oxide releasing agents) (about 0.05g), and the right paw was topically administered with calcium channel blocker ointment in the same manner. After administration, the rat was fixed by a fixed cylinder for about 4 hours. After 4 hours, the rat was released, wiped with water to remove the residual medicament on the administered site, and returned to the cage. The gavage frequency of the VEGFR/VEGF inhibitors is shown in Table 18. The rat was subject to gavage with the VEGFR/VEGF inhibitors, until the paw administered with calcium channel blocker ointment developed the symptoms of hand-foot syndrome or the rat died. After 15-18 days of administration, the number of rats in which the paw administered with nitroglycerin ointment (or the other nitric oxide releasing agent) exhibited normal or significantly less serious than the paw administered with the calcium channel blocker ointment was counted as the number of rats in which the hand-foot syndrome was effectively prevented.

Table 18 lists the combination of experiments of 0.2% nitroglycerin ointments (or the other nitric oxide releasing agent) and calcium channel blocker ointment, and the corresponding experimental results (wherein, the value in the relative ameliorated rate column = the number of rats in which the hand-foot syndrome on the left paw was significantly less serious than the hand-foot syndrome on the right paw in each group/the hand-foot syndrome model in each group $\times 100\%$).

Table 18 Experimental Conditions and Results of Examples 148-159

Experiment No.	VEGFR inhibitor	Dosage	Frequency	Administration		Administration Days	Relative Ameliorated Rate
				Left	Right		
148	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	0.2% Diltiazem ointment	15	83.33%
149	Apatinib	105mg/kg	once per day	0.2% Nitroglycerin ointment	0.2% Diltiazem ointment	15	60%
150	Lenvatinib	100mg/kg	twice per day	0.2% Nitroglycerin ointment	0.2% Diltiazem ointment	18	77.78%
151	Regorafenib	90mg/kg	once per day	0.2% Nitroglycerin ointment	0.2% Diltiazem ointment	18	75%
152	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	0.2% Verapamil ointment	15	71.43%
153	Sorafenib	80 mg/kg	once per day	0.2% Nitroglycerin ointment	0.2% Nifedipine ointment	15	66.67%
154	Sorafenib	80 mg/kg	once per day	0.2% Isosorbide dinitrate and isosorbide mononitrate mixed ointment	0.2% Diltiazem ointment	15	60%
155	Sorafenib	80 mg/kg	once per day	0.2% Isosorbide dinitrate and isosorbide mononitrate mixed ointment	0.2% Nifedipine ointment	15	66.67%
156	Sorafenib	80 mg/kg	once per day	0.2% Isosorbide dinitrate and isosorbide mononitrate mixed ointment	0.2% Nifedipine ointment	15	60%
157	Sorafenib	80 mg/kg	once per day	0.2% Nicorandil ointment	0.2% Diltiazem ointment	15	66.67%
158	Sorafenib	80 mg/kg	once per day	0.2% Nicorandil ointment	0.2% Verapamil ointment	15	57.14%
159	Sorafenib	80 mg/kg	once per day	0.2% Nicorandil ointment	0.2% Nifedipine ointment	15	62.5%

NOTE: The modelling success rate of anti-cancer medicaments are not constant: the success rate of the hand-foot syndrome model in each group is 30% to 90%, that is, there are about 3-9 successful hand-foot

syndrome models among 10 rats, during the modelling process, death of individual rat or unsuccessful modelling in different administration groups. The control rate refers to the ratio of the number of rats in which the symptoms on the paw administered with nitroglycerin ointment are less serious than the paw administered with other medicaments to the total number of the hand-foot syndrome model rats in the experimental groups.

FIG 27 shows the conditions of the left paw, front side, and right paw of a typical rat in the administration groups of examples 148-153 after it was topically administered on its left paw (with 0.2% Nitroglycerin ointment) and on its right paw (with 0.2% Diltiazem ointment). FIG. 28 shows the conditions of the left paw, front side, and right paws of a typical rat in the administration group of examples 154 after it was administered on its left paw (0.2% Isosorbide dinitrate and isosorbide mononitrate mixed ointment) and on its right paw (0.2% Diltiazem ointment).

It can be seen from the results in Table 18 and FIG 27 that as compared with 0.2% calcium channel blocker ointment, 0.2% nitroglycerin ointment and other nitric oxide releasing agent are capable of effectively controlling the hand-foot syndrome caused by the VEGFR/VEGF inhibitor.

Preferred embodiments of the present application are described herein, including the best mode known by the inventors for carrying out the application. Upon reading of the description, variations of those preferred embodiments will be apparent to those of ordinary skill in the art. The inventors expect that the skilled person can apply such variants if required, and the inventors intend to implement the present application in a manner other than those specifically described herein. Thus, the present application includes all the modifications and equivalents of the subject matter described in the appended claims as permitted by applicable laws. Moreover, the present application includes any combination of all possible variations of the aforesaid elements, unless otherwise indicated or clearly contradict with the context.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement or any form of suggestion that such prior art forms part of the common general knowledge.

It will be understood that the terms “comprise” and “include” and any of their derivatives (e.g. comprises, comprising, includes, including) as used in this specification, and the claims that follow, is to be taken to be inclusive of features to which the term refers, and is not meant to exclude the presence of any additional features unless otherwise stated or implied.

In some cases, a single embodiment may, for succinctness and/or to assist in understanding the scope of the disclosure, combine multiple features. It is to be understood that in such a case, these multiple features may be provided separately (in separate embodiments), or in any other suitable combination. Alternatively, where

separate features are described in separate embodiments, these separate features may be combined into a single embodiment unless otherwise stated or implied. This also applies to the claims which can be recombined in any combination. That is a claim may be amended to include a feature defined in any other claim. Further a phrase referring to “at least one of” a list of items refers to any combination of those items, including single members. As an example, “at least one of: a, b, or c” is intended to cover: a, b, c, a-b, a-c, b-c, and a-b-c.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating a disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject, wherein the disease or disorder is hand-foot syndrome, the nitric oxide releasing agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, sodium nitrate, isoamyl nitrite, sodium nitrite, molsidomine, sodium nitroprusside, S-nitrosothiol silica nanospheres, S-nitrosoethanedithiol chitin, oligo-propylenediamine-grafted chitosan NONOate, N-nitrosodibutylamine, hydroxyldiazenesulfonic acid-1-oxide disodium salt, streptozocin, nicorandil, and *Nitrosomonas europaea*, and the concentration of said nitric oxide releasing agent is about 0.05% (w/w) to about 0.5% (w/w).
2. The use of claim 1, wherein said disease or disorder is caused by said administration of a VEGFR inhibitor and/or a VEGF inhibitor.
3. The use of any one of claims 1-2, wherein said VEGFR inhibitor and/or VEGF inhibitor is for treating tumors.
4. The use of any one of claims 1-3, wherein location of said disease or disorder is different from that of tumor.
5. The use of any one of claims 1-4, wherein said VEGFR inhibitor and/or said VEGF inhibitor comprises Ramucirumab, Bevacizumab, Regorafenib, Ponatinib, Cabozantinib, Lenvatinib, Sorafenib, Pazopanib, Apatinib, Axitinib, Nintedanib, Vandetanib, Sunitinib, Midostaurin, Tivozanib, Fruquintinib, Cediranib, Brivanib, Donafenib, Sulfatinib, Anlotinib, Famitinib, Tesevatinib, Vorolanib, Motesanib, Linifanib, Semaxanib, Dovitinib, Orantinib, Vatalanib, Telatinib, Glesatinib, Delitinib, Ilorasertib, Rebastinib, Golvatinib, Foretinib, Ningetinib, Tafetinib, Altiratinib, TAS-115, Chiauranib, Henatinib, 4SC-203, AAL-993, ACTB-1003, AEE-788, AMG-628, Arenobufagin, BAW2881, BIBF-1202, BMS-690514, BMS-794833, CEP-11981, CEP-5214, CP-547632, CYC116, DW532, ENMD-2076, FIIN-1, GFB-204, BFH-772, BMS599626, BMS690514, PP 121, MGCD 265 analogue, AC480, Ki 8751, KRN 633, WHI-P 154, TAK593, JI 101, AZD-2932, SCR-1481B1, Isoliquiritigenin, JNJ-26483327, KI-20227, LY2457546, ODM-203, OSI-930, PF-00337210, CGP41231, R1530, RAF265, SAR131675, Semaxinib, SIM010603, SKLB1002, SKLB610, SU 5205, SU11652, SU14813, SU-1498, SU-4312, SU5402, T-1840383, Tanshinone IIA, TAS-115, TG 100572, TG 100801, TG100572 HCl, Toceranib, Tyrosine phosphorylation inhibitor A9, Tesevatinib, XL-844, XL999, ZD4190 HCl, ZM-306416, ZM323881 HCl, ABT-510, NVP-ACC789, ADT-OH, BMS-645737, EG 00229,

XL-820, SGI-7079, Endostatin, Taxifolin, Aflibercept, a pharmaceutically acceptable salt thereof and/or any combination of the foregoing.

6. The use of any one of claims 1-5, wherein said disease or disorder is caused by the VEGFR and/or VEGF inhibition.

7. The use of any one of claims 1-6, wherein severity of said a disease or disorder associated with administration of said VEGFR inhibitor and/or VEGF inhibitor is Grade 1 or above, Grade 2 or above, Grade 3 or above, Grade 4 or above, and/or Grade 5 or above according NCI-CTCAE V5.0.

8. The use of any one of claims 1-7, wherein the nitric oxide releasing agent is nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or sodium nitroprusside.

9. The use of any one of claims 1-8, wherein the nitric oxide releasing agent is nitroglycerin.

10. The use of any one of claims 1-9, wherein said medicament is formulated to be suitable for topical administration, and/or said medicament is formulated as ointment.

11. The use of any one of claims 1-10, wherein said medicament does not substantially affect the therapeutic effect of a VEGFR inhibitor and/or a VEGF inhibitor.

12. The use of any one of claims 1-11, wherein said subject comprises a cancer patient; and/or said subject has been, is being and/or will be administrated said VEGFR inhibitor and/or said VEGF inhibitor; and/or said subject suffer or susceptible to suffer said disease or disorder associated with administration of a VEGFR inhibitor and/or VEGF inhibitor; and/or said subject has not suffered said disease or disorder before administrating said VEGFR inhibitor and/or VEGF inhibitor.

13. The use of any one of claims 1-12, wherein a severity of said disease or disorder increases after administrating said VEGFR inhibitor and/or VEGF inhibitor.

14. A method comprising administrating a nitric oxide releasing agent to a subject, and said subject has been, is being and/or will be administered a VEGFR inhibitor and/or VEGF inhibitor, and suffers a disease or disorder associated with administration of said VEGFR inhibitor and/or VEGF inhibitor, wherein the disease or disorder is hand-foot syndrome. the nitric oxide releasing agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, sodium nitrate, isoamyl nitrite, sodium nitrite, molsidomine, sodium nitroprusside, S-nitrosothiol silica nanospheres, S-nitrosoethanedithiol chitin, oligo-propylenediamine-grafted chitosan NONOate, N-nitrosodibutylamine, hydroxyldiazenesulfonic acid-1-oxide disodium salt, streptozocin, nicorandil, and *Nitrosomonas europaea*, and the concentration of said nitric oxide releasing agent is about 0.05% (w/w) to about 0.5% (w/w).

15. A method of preventing or treating a disease or disorder, comprising administrating nitric oxide

releasing agent to a subject that suffers said disease or disorder, and said disease or disorder is hand-foot syndrome, wherein said subject has been, is being and/or will be administrated a VEGFR inhibitor and/or VEGF inhibitor, the nitric oxide releasing agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, sodium nitrate, isoamyl nitrite, sodium nitrite, molsidomine, sodium nitroprusside, S-nitrosothiol silica nanospheres, S-nitrosoethanedithiol chitin, oligo-propylenediamine-grafted chitosan NONOate, N-nitrosodibutylamine, hydroxyldiazenesulfonic acid-1-oxide disodium salt, streptozocin, nicorandil, and *Nitrosomonas europaea*, and the concentration of said nitric oxide releasing agent is about 0.05% (w/w) to about 0.5% (w/w).




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14



FIG. 15




FIG. 16




FIG. 17



FIG. 18


Tumor volume(mm³)

FIG. 19

HUVEC 24h




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28